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ABSTRACT
TISSUE ENGINEERED MICRO AND MACROVASCULATURE UTILIZING
STROMAL VASCULAR FRACTION
Joseph Samir Zakhari
April 19, 2018

This dissertation describes the use of stromal vascular fraction to tissue engineer
3D microvasculature and macrovasculature.

Stromal vascular fraction is an easily

isolatable cell source from adipose tissue depots. It has demonstrated remarkable potential
both in vitro and in vivo for forming microcirculation capable of perfusion upon
implantation. SVF is clinically utilized as a therapeutic cell source for anti-inflammation
for osteoarthritis and is being studied for ischemic tissue application to stimulate
revascularization.
The work described herein is divided within four chapters. Chapter I provides an
introductory overview and lists the aims and hypothesis for the dissertation. Chapter II
describes experiments towards elucidating specific aim 1: determine the mechanism by
which SVF forms neovascular networks in 3D fibrin gels in vitro. This was accomplished

through a multitude of experiments describing SVF undergoing vasculogenesis and
angiogenesis in a 2D automated in vitro assay, and the ability to inhibit these processes via
NOTCH and PDGF-B/PDGFR-b interruption. These mechanisms, as well as integrin
dependent mechanisms, were analyzed within 3D fibrin and 3D collagen I culture systems
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as well. It is believed that the activation of the fibrin specific integrin aVb3 plays a role in
hyper-stimulating fibrin-embedded endothelial cells in a VEGF dependent manner.
Chapter II describes experiments towards understanding specific aim 2: create
deliverable tissue units of SVF-derived microvasculature or macrovasculature
utilizing bioprinting, and electrospinning technologies. This was accomplished through
bioprinting spheroids containing cells embedded in collagen I or fibrin using
superhydrophobic surface technology or electrospinning varying porosities of PCL and
pressure sodding SVF cells into the material. It is possible to automate and create dosable
units of microvascular tissue in spheroid format using SVF cells, ECM such as fibrin or
collagen I, and bioprinting technologies. Additionally, it is possible to create blood vessel
mimics of multiple porosities in order to retain and allow cellular infiltration within the
biomaterial. Chapter IV is an overall summary and conclusion of the dissertation. These
studies could hopefully generate more knowledge on the creation of tissue engineered
microvasculature and microvasculature for use in treating ischemic cardiomyopathies.
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CHAPTER I
INTRODUCTION

Ischemic Cardiovascular Disease
Cardiovascular disease is a growing concern in the western world. The American
Heart Association in 2017 states that an estimated 92.1 million adults in the United States
have at least one type of cardiovascular disease (CVD), and by 2030, 43.9% of the
population is projected to have some form of cardiovascular disease1. Due to increase in
treatments of acute conditions and better therapies, death rates due to CVD have declined
by 25.3% since 20041. While deaths have declined, the growing rates of cardiovascular
disease can still be attributable to smoking and tobacco use, physical inactivity, poor
nutrition, obesity, high blood cholesterol, high blood pressure, and increases in type II
diabetes and metabolic syndrome.
Smoking and tobacco usage has decreased over the past ten years, (15.2%) but with
changing technology, there has been increases in e-cigarette usage especially in middle
school (5.3%) and high school (16.0%) students. In addition to tobacco usage, only 27.1%
of high school students meet the 60 minutes or more per day physical activity
recommendations in 20151. The increase in obesity from 2000 to 2013 was significant in
adults and youth, however, obesity rates have begun to level off, according to the most
recent AHA statistics. Cholesterol lowering drugs such as statins have increased in usage
from 7 to 17% from the years 1999 – 2012 alone, trending with the decrease in the age-
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adjusted blood levels of low-density lipoprotein cholesterol (126mg/dL to 111mg/dL; 1999
to 2014) as well as the age-adjusted prevalence of high-density lipoprotein cholesterol
(42.9% to 28.5%, 1999 to 2014 respectively). Hypertension in US adults in 2014 was
estimated to be 34%, totaling 85.7 million adults, and in children to adolescents 8 to 17
years old, the prevalence of borderline to high blood pressure was noted at 11%.
Controlling hypertension in both adults and adolescents with stage 2 hypertension is a
foundational therapy which can potentially be cost saving for CVD associated
hospitalizations in the future. The most recent statistics show that an estimated 23.4 million
US adults have diabetes mellitus with 7.6 million remaining undiagnosed and 81.6 million
having prediabetes1. Even with some promising statistics, it should be noted however that
CVD and associated hospital costs can provide a devastating burden to the socioeconomic
structure of the American health care system in years to come.
There are many types of CVD, but of the acute types, where the majority of
hospitalizations are required, these can be attributed to myocardial infarction brought on
by coronary artery disease or acute coronary syndrome. Coronary artery disease is
described as a pathogenesis in which an atherosclerotic plaque high in low-density
lipoprotein builds up on the intimal surface of the coronary artery in areas of endothelial
cell damage, causing increased inflammation, lipoprotein retention, and foam cell
formation with subsequent luminal narrowing and thrombosis or rupture of plaque, sending
lipid-rich emboli distally, leading to incomplete or complete occlusion of downstream
coronary branches and loss of oxygen rich blood delivery to the myocardium.
Atherosclerosis can affect the coronary arteries, abdominal aorta, thoracic aorta, circle
Willis, and popliteal arteries.
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However, regardless of location, the pathogenesis remains the same.
Atherosclerosis begins with the depositing of fatty streaks at areas of significant turbulent
blood flow causing additional hemodynamic stress and damage to the underlying
endothelium.

These damaged cells subsequently upregulate adhesion molecules for

neutrophilic and monocytic binding and infiltration2 as well as lose functional adherens
junctions between cells allowing for increased LDL entry into the sub-intimal space3.
Increase in LDL stores sub-intimally leads to inappropriate oxidation of LDL which
exacerbates monocyte recruitment to the area.

The oxidized LDL along with

Apolipoprotein B are phagocytosed by the recruited monocytes/macrophages, however,
the enzymatic ability of the cells become limited and as such, huge deposits of oxidized
LDL remain within the cell giving the cell a histological ‘foamy’ appearance, thus termed
foam cells4.

Foam cells indeed are highly inflammatory due to increased cytokine

production and release, ultimately stimulating local smooth muscle cell proliferation and
production and secretion of collagen. As such, a positive feedback loop occurs causing
increased recruitment of monocytes, increased LDL storage, increased damage to
underlying smooth muscle cells, and pathophysiologic change from a ‘fatty streak’ to an
atherosclerotic plaque5. The developing atherosclerotic lesion can itself reduce luminal
size, reduce distal blood flow via occlusion or thrombotic formation at the lesion as well
as weaken and rupture sending emboli distally all while increasing vessel wall stress and
proximal aneurysm formation. Regardless of late stage rupture or thrombosis, both
ultimately lead to cessation of physiologic blood flow, infarction and tissue necrosis.
At the coronary artery, non-restorative loss of blood flow leads to tissue apoptosis
and necrosis, termed clinically a transmural infarct if involvement occurs from
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endocardium through the myocardium, i.e., greater than 50% of the thickness of the
ventricular wall.

Initial infarct size grows in a waveform state in which collateral

microvessels cannot support the needs of the surrounding tissue to the primary infarct zone
and subsequently undergo apoptosis and necrosis as well, termed the ‘border zone’ of
infarct where it is argued that this tissue is most responsive to clinical revascularization.
Cell viability may be preserved if blood flow is restored immediately post infarct
(20-40min). Indeed, within seconds of loss of myocardial blood supply, cardiomyocytes’
aerobic glycolysis ceases leading to inadequate ATP and production of lactic acid with a
functional loss of contraction within just a minute of ischemic insult. On a subcellular
level, mitochondrial swelling is noticed along with myofibrillar relaxation and glycogen
depletion. If the ischemic insult lasts more than 40 minutes, coagulative necrosis takes
place. Overtime, both gross and microscopic findings of the affected tissue demonstrate
an infarct that remodels first through a highly infiltrated granulation tissue, subsequent
robust angiogenesis but latter angioregression6,7, and finally, a dense, avascular
collagenous scar, ultimately affecting multiple functions, including contractility as well as
signal transduction from pacemaker cells8,9.
If patients do survive the initial infarct, remodeling of the tissue occurs and can lead
to infarct expansion, loss of muscle density, and left ventricular systolic failure potentially
leading to congestive heart failure if chronically left untreated. What governs the location,
size, and morphological features of acute MI ultimately depend on 1) location, severity and
rate of coronary occlusion, 2) size of the vascular bed perfused by the obstructed vessel(s),
3) duration of the occlusion, 4) metabolic demands of the myocardium, and 5) the extent
of collateral blood supply that may provide support to the ischemic tissue.
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While most attribute MI to coronary artery atherosclerosis, the microvasculature of
the heart and the downstream reperfusion even after surgical coronary artery bypass
grafting (CABG) are instrumental in functional retention of the myocardium. Indeed,
because of the high metabolic demand of the heart, the microvasculature makes up 37% of
the total volume of the heart10. Even post CABG, a phenomenon called no-reflow may
occur in which conduit vessel perfusion is not satisfactory to perfuse downstream
microvasculature in the affected tissue11. While this phenomenon is not well understood,
it is hypothesized that redistribution of flow via microvessels away from the necrotic core
is a saving mechanism for the surrounding host tissue not damaged by ischemic insult, and
that the redirection of flow increases areas in which microvessels can rupture or form
aneurysms within the necrotic zones. However, the border zone infarct is significantly
depleted of oxygen rich blood in severe cases of no-flow as well12.
Current approved therapies for acute myocardial infarction include surgical and
non-surgical techniques in order to correct the coronary artery insult. Of the surgical
techniques coronary artery bypass grafting is a predominant treatment today in which either
the saphenous vein or the left internal mammary artery (LIMA) is harvested to use as a
conduit vessel to circumvent the blockage within the native coronary vessel. The LIMA is
the vessel of choice with greater than 90% of patients retaining patency over a 10-year
period and less than 4% developing any atherosclerosis of hemodynamic significance.
Saphenous vein is a secondary vessel used, however, as current statistics demonstrate, up
to 25% of saphenous grafts occlude within 1 year post-operatively13. The procedure was
first established by Debakey and Favaloro in 1968 and is still the predominant surgical
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procedures used today14-16. The peak number of operations were roughly 519,000 in 2000
and has declined to about 300,000 in 201213.
Non-surgically, percutaneous transluminal coronary angioplasty or stenting is a
common treatment to relieve angina as well as acute MI due to coronary occlusion. Briefly,
a catheter is inserted into the arterial circulation usually through the groin or femoral artery
and advanced retrograde against blood flow into the coronary artery of interest. After
angiography, a balloon at the end of the catheter is inflated widening the lumen of the
vessel at the point of plaque narrowing, in addition, expandable mesh stents can be
deployed intra-arterially around the balloon and be retained within the vessel wall to
provide mechanical integrity in order to keep the lumen patent. PTCA was first performed
by Andreas Gruntzig in 1977 and is still used today17-19.
More recent efforts to elucidate stem cell therapies and other cellular
transplantation have been forefront in cardiac regenerative medicine as of recent. Most of
these therapies involve isolating adult cardiac stem cells from patient tissue such as atrial
appendage in order to culture expand and reintroduce to the damaged myocardium.

The

idea being that the ckit positive adult cardiac stem cells will localize to areas of insult and
replenish damaged cardiomyocytes, indeed, endogenous cardiac myocytes cannot replicate
and self-heal. A key phase one clinical trial called SCIPIO was performed in which
patient’s own ckit+ adult cardiac stem cells were isolated, expanded, and reintroduced to
the damaged myocardium through coronary balloon occlusion and release of cells
intravascularly. However, less than 2% of the cells homed and resided in the heart tissue
with most localizing to the liver, lungs and kidneys. As such, while some patients
experienced increases in ejection fraction and other beneficial hemodynamic measures, it
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was concerning that the cell-based therapies were not retained, and rather, paracrine
mechanisms may be at play20-22.
The SCIPIO trial, and others utilizing stem cells, focus on the endpoint of ejection
fraction due to functional mass increase of myocardium without addressing a key concern
post MI as alluded to prior: the dysfunction of microcirculation within the ischemic tissue.
It is imperative to restore vascular supply to retain and support endogenous cardiac
myocytes as well, and as such, seems logical to introduce cells that reproduce
microvasculature as well. Indeed, animal studies utilizing heterogenous cell populations
like SVF contained within tissue engineered constructs retain cell populations at areas of
surgical implant. Leblanc and colleagues created a hybrid vascular graft patch for the
pericardium of animals undergoing left coronary artery ligation to aid in systolic function
of the ischemic tissue. This graft was made of a vicrylTM mesh support system housing
adipose-derived stromal vascular fraction cells (SVF) embedded within the pores. In the
presence of both vicrylTM and cells, increased hemodynamic pressures specifically
demonstrating improved systolic function were noted in addition to increased microvessel
density and perfusion at site of SVF patch implant23.

As such, tissue engineered

microvasculature may be an alternative roadmap to follow for future cell-based therapies
for ischemic cardiomyopathies.

The Circulatory System
The vasculature is a complex organ within the body that serves to provide
oxygenated blood to tissues and remove waste and metabolites as well as circulate
deoxygenated blood back to the heart and lungs. It is a complex system made up of a
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multitude of cell types that form distinct hierarchical structures including arteries,
arterioles, veins, venules, and capillaries.
Arteries function to carry oxygenated blood from the lungs and heart to deliver to
the peripheral and visceral organs. As mainly conduit vessels, their structure resembles
their function. At the macroscopic level, arteries can be divided into 3 main layers. These
layers are the tunica intima, the tunica media, and the tunica adventitia. The tunica intima
is comprised of a single layer of endothelial cells as well as a basement membrane/internal
elastic membrane, the latter of which provides polarity and a diffusion barrier to proteins
crossing the endothelial cell layer from the lumenal blood.
Adjacent to the internal elastic lamina resides the tunica media composed
predominantly of smooth muscle cells. The tunica media functions to respond to luminal
sheer and pressure signals sent from the endothelium, as well as juxtacrine and paracrine
signaling to either contract or relax, thereby changing the diameter of the vessel. These
smooth muscle cells maintain what is known as vascular tonicity. The tunica media is
physically separated by the external elastic membrane or external elastic lamina from the
final layer, the tunica adventitia.
The tunica adventitia is the outermost layer of the vessel and is made up of
fibroblasts, resident immune cells, connective tissue, and perivascular nerves. It was once
believed to be a layer of purely structure and separation from surrounding tissues, but now
there is much debate regarding resident immune cell signaling as important mediators of
vascular function in both diseased and non-diseased states24.
If we continue to follow blood flow from the arteries we move to arterioles which
have decreased diameters and regulate the flow of blood to a higher extent due to their
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thick tunica media with smooth muscle cells aligned concentrically as well. They are
known as the resistance vessels within the body. Upon constriction or dilation, arterioles
can regulate the flow of blood into the downstream capillary beds. It is here at the capillary
where nutrient and gas exchange predominantly occurs. Capillary lumens are quite small
ranging from about 5-10 µm in diameter, roughly the size of a single red blood cell. The
diameter change allows for blood cells to pass through at low velocity such that gaseous
material and small molecules could be transferred between the blood cell, endothelium,
and tissue to allow for tissue oxygenation and waste removal.
Capillary beds are highly specialized for certain functions depending on the organ
in which they perfuse. More specifically, there are three types of capillaries: continuous,
fenestrated, and sinusoidal. Continuous capillaries are those in which endothelial cells
retain tight junctions or zonula occludens/adherens where the junctions exhibit vascular
cadherins (i.e. VE-cadherin), proteins which link adjacent cells together in a fashion that
restricts the ability of large proteins to cross between cells. Along with tight junctions,
continuous capillaries also have a continuous basement membrane on the basal side of the
cell. Basement membranes are proteinaceous complexes made of collagen IV, laminins,
hyaluronic acid, and other proteins. They present an additional physical as well as charge
barrier to any large molecule or protein trying to cross from luminal space to tissue space,
and vice versa. These structural barriers are important in areas of the body that have to
limit protein or large molecule movement from the circulation into the tissue. Such an
example would be the blood brain barrier which is predominantly made up of continuous
capillaries that exhibit zonula occludens. The next type of capillary is the fenestrated
capillary.

Fenestrated capillaries like continuous capillaries have a continuous,
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uninterrupted basement membrane, however, there exists windows within endothelial cells,
small openings on the order of 60-80 nm which allow transvascular exchange of small
molecules and proteins. Such capillaries can be found in organs such as the small intestine,
pancreas, and kidney where proteins and hormones need to transfer from tissue space into
circulation and vice versa. The final type of capillary is sinusoidal capillaries. Unlike
fenestrated and continuous capillaries, sinusoidal capillaries have discontinuous basement
membranes and endothelial junctions which allow for the passage of large substances, as
large as 30-40 µm to cross, such as red blood cells, white blood cells, albumin and other
plasma proteins, bilirubin, etc. Organs that contain sinusoidal capillaries include the
spleen, liver, lymph nodes, and bone marrow.
After nutrient exchange occurs at the capillaries, deoxygenated blood returns
through venules and veins back to the right heart to be pumped into the lungs for
reoxygenation. Venules and veins contain the same cell types as arterioles and arteries,
however they are more compliant usually with less smooth muscle cells. In other words,
they store a lot of the blood volume and can stretch to accommodate larger volumes.
Interestingly, returning deoxygenated blood back to the heart would be a concern when
working against gravity, however, this is mitigated by the presence of one-way valves in
conjunction with skeletal muscle pumps that facilitate unidirectional movement back
towards the inferior and superior vena cava. These valves are endothelial flaps that are
unique to the venous and lymphatic side of the circulatory system.
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Development of the Circulatory System; Vasculogenesis and Angiogenesis
The mammalian circulatory system develops initially utilizing two processes:
vasculogenesis and angiogenesis. Vasculogenesis is the differentiation and assembly of
individual endothelial cells into blood vessels in situ. Usually this event is initiated
extraembryonically, associated with the formation of blood islands within the yolk sac.
Blood islands are groupings of hemangioblasts, cells that are hematopoetic precursors as
well as angioblasts which form the vessel proper. The other type of vasculogenesis occurs
intraembryonically.

More specifically, intraembryonic vasculogenesis occurs when

angioblasts within the aorta-gonad-mesonephros differentiate to form the dorsal aorta and
the cardinal veins. The dorsal aorta fuses with differentiated angioblasts that arose from
the cranial mesoderm, which at this point in embryonic development forms the
endocardium of what will be the heart. These two systems fuse and ultimately remodel to
the endocardial tube, the plexus of endothelial cells that ultimately will form the heart and
aorta. It is argued from this point forward that intraembryonic development is primarily
through angiogenesis, the growth of new blood vessels from preexisting ones.
Angiogenesis occurs through predominantly two mechanisms.

The classical

mechanism is sprouting, where endothelial cells migrate away from nascent vasculature
into the tissue to establish a new vascular bed. Sprouting occurs via production and
secretion of matrix metalloproteases, enzymes which help degrade surrounding matrix
outside the vessel within the tissue of interest, as well as parts of the vessel connective
tissue itself, to subsequently allow endothelial cell migration through a more porous
microenvironment. Sprouting angiogenesis is activated via a chemotactic gradient of
specific growth factors such as hypoxia inducible factor 1 alpha (HIF1a) and vascular
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endothelial growth factor (VEGF), which stimulate endothelial cells to migrate into low
oxygen tension, avascular tissues, mechanisms which will be described in detail further.
The second type of angiogenesis is known as intussusception, which is the mechanism in
which existing blood vessels, usually, smaller vessels such as capillaries, pinch inward
within the lumen, splitting one vessel into two or more vessels, a phenomenon highly
dependent upon pericytyes and surrounding matrix interaction and stability. The initial
description and use of the term angiogenesis was by John Hunter in the 1780’s. Judah
Folkman and colleagues in the early 1970s proposed that angiogenesis was a major
contributor to the expansion of solid tumors25-27.
The molecular mechanisms involved in vascuologenesis and angiogenesis are quite
complex, however, several known growth factors are key players in both events.
Beginning early in vasculogenesis, hemangioblasts must get signaling to differentiate from
the mesoderm and follow a path to nascent vessel formation. Fibroblast growth factor
(FGF) and bone morphogenic protein (BMP) families of growth factors are the primary
cue for this differentiation cascade to occur28-31. Fibroblast growth factor consists of two
predominant forms, acidic and basic FGF. There are a total of 15 FGF members, all
containing heparin-binding motifs32. To understand FGF’s role in vascular development,
FGF2 knockout animals were studied. Interestingly, the knockout was not lethal, however,
mice had decreased vascular tone and low blood pressure as compared to wild type 33,34.
On the other hand, overexpression of the gene led to tumors that were highly angiogenic
in nature 35.
An extremely important factor regulating angiogenesis both during embryonic
development and throughout life is the secretion of vascular endothelial growth factor

12

(VEGF). The VEGF family contains 7 members: VEGF-A (5 isoforms 121, 145, 165, 189,
and 206 amino acids), VEGF-B, VEGF-C, VEGF-D, VEGF-E, svVEGF, and placental
growth factor (PlGF) with VEGF-A the most notable upregulated form found in a variety
of solid human cancers and lymphomas. The cells that respond to VEGF are those that
have VEGF-Receptor 1 (FLT-1) and VEGFR-2 (FLK-1), which happen to be restricted to
only endothelial cells36. VEGF initially was discovered in the early 1980s by Senger and
colleagues where they witnessed tumor cells secreting a substance that made vasculature
leaky and increased the production of ascites fluid. As such, VEGF was initially described
as Vascular Permeabilty Factor (VPF) 37. Continually studies into the late 1980s changed
the name from VPF to VEGF. Indeed, it was found that VPF was a mitogen that played a
key role in tumor angiogenesis38. VEGF, unlike FGF is instrumental to embryo survival.
Loss of a single copy of the VEGF gene results in embryonic lethality. VEGF is such an
incredible inducer of angiogenesis that inhibitors of the molecule have been studied
clinically as treatments for highly vascularized tumors and metastatic cancers. Avastin
(bevacizumab) is a well-known example cleared for use by the FDA in 2004 for metastatic
cancer of the colon and rectum39.
Angiogenesis as aforementioned is the sprouting and migration of endothelial cells
away from an established vessel in order to infiltrate new tissue, lumenize and create a new
branch or vessel to provide the oxygen and nutrients necessary to that tissue. The original
endothelial cell migrating is known as the tip cell, where the subsequent endothelial cell
following behind is known as the stalk cell. Local hypoxia is a key trigger of angiogenesis
where HIF1a stimulates the production of VEGF which acts as a chemoattractant to
endothelial cells. The first cell migrates away due to the high production of matrix
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metalloproteases and active cytoskeletal rearrangement with high presence of filipodia on
the cell surface. Intricate signaling takes place between the tip cell and the subsequent
stalk cell behind which dictates phenotype of each endothelial cell. Specifically, VEGF
binding to VEGFR2 increases the expression of delta-like ligand 4 (Dll4) on tip cells which
activates NOTCH signaling on the adjacent stalk cell. Notch is cleaved by ADAM and gsecretase which solubilizes the intracellular domain NICD, a transcription factor which
downregulates VEGFR2 and upregulates Wnt and VEGFR1, pushing the cell to retain a
stalk cell phenotype; unlike the tip cell which has high filipodia, motility, and expression
of VEGFR2 on the cell surface40.
Individual tip and stalk cells undergo tubulogenesis as well to establish a lumen.
Cell hollowing and cord hollowing are the established models for tubulogenesis. In cell
hollowing, endothelial cells undergo pinocytosis, vacuolar formation and continual fusion
to create a hole or lumen within and individual endothelial cell. Exocytosis between cells
at basolateral surfaces create a continuous lumen. Polarity is established upon complete
lumen formation of single endothelial cells aligned next to one another. In cord hollowing,
endothelial cells lose apical to basal polarity. Signaling externally, pinocytotic vesicles
carry apical markers and fuse between multiple endothelial cells’ membranes. A tube in
cross section in the cord model will be made of two or more endothelial cells while a tube
in cross section in the cell hollowing model will only contain one nucleus, one endothelial
cell41.
The endothelial cell in addition to forming the lining of the vasculature also
modulates vasodilation, vasoconstriction, inflammation, oxidative phosphorylation and
thrombosis in order to maintain homeostasis of the local microenvironment. Vasodilation
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and vasoconstriction are predominantly through endothelial cell production of nitric oxide,
a potent vasodilator produced through the enzyme endothelial nitric oxide synthase
(eNOS)42. Nitric oxide diffuses into the smooth muscle layer of the vessel and promotes
recycling of ADP and ATP to relax smooth muscle cells. On the other end, endothelial
cells produce endothelin and prostanoids which are potent vasoconstrictors. eNOS itself
can be increased in the presence of VEGF, serotonin, adenosine, and bradykinin43,44. Nitric
oxide also can decrease inflammation and oxidative phosphorylation leading to a decrease
in reactive oxygen species45. The endothelial cell in addition, regulates diapedesis and the
transfer of white blood cells from the circulation into the surrounding tissue under
inflammatory responses by upregulating cell surface adhesion molecules Selectin and
ICAM46.
A final set of mechanisms to discuss that are pivotal to formation of functional,
non-leaky microvasculature is the paradigm in which newly formed endothelial tubes
recruit and communicate with perivascular support cells, pericytes in order for vessel
maturation to occur. During sprouting angiogenesis, endothelial cells secrete the ligand
platelet-derived growth factor B. The concomitant receptor for this ligand is PDGFRb
which is found on co-migrating pericytes. In studies where mice had knockout PDGFRb
or PDGFB, mural cell deficiency and widespread vascular leakage led to perinatal lethality,
in addition to the absence of glomerular tufts within the kidneys47.
Once pericytes are recruited to endothelial networks they produce tight adhesions,
N-Cadherins to maintain position with the endothelial cell. Additional signaling occurs
where the pericyte or mural cell now produces angiopoetin-1, a paracrine factor stimulating
the production of the Tie 2 receptor on the endothelial cell which is imperative for continual
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endothelial cell survival, angiogenesis, and additional mural cell attachment and retention.
Mice lacking the Tie2 receptor develop cardiac defects, edema, and hemorrhage and die in
utero48.
A sphingosine, lipid derived molecule known as S1P is produced by platelets and
hematopoetic cells to activate endothelial differentiation gene (Edg) receptors on
endothelial cells. Upon Edg activation, G-protein coupled signaling and downstream
MAPK and Rac cascades are activated in order to increase production and trafficking of
N-Cadherin to adherens junctions in order to maintain tight association with mural cells.
Additionally, however, in a g protein coupled independent manner, Rho cascades are also
activated to increase the production and trafficking of VE-Cadherin. Indeed, S1P mutants
in utero between weeks 14 and 15 develop severe edema and fatal hemorrhages49.
Pericytes can differentiate into mural cells and subsequently smooth muscle cells
through the induction of TGF-b signaling through the activing receptor kinase Alk5.
Activation of Alk5 leads to phosphorylation of Smads 2/3, transcription factors that
regulate genes such as SM22a, connexin 37, fibronectin, and others which decrease cell
migration and proliferation while increasing smooth muscle differentiation and subsequent
vessel maturation50. All these intricate mechanisms are important to develop functional,
non-leaky vasculature through vascuolgeneis and angiogenesis.

Tissue Engineering Vascular Structures
Tissue engineering utilizes concepts from biology and bioengineering to produce
biomass in vitro resembling endogenous tissues for potential therapeutic benefit. Usually,
experiments involve the use of highly adaptive and specific cells grown in an extracellular
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matrix that allows for cell function to occur as well as provide a 3D microenvironment
resembling native tissue stroma, with the hopes that post maturation in vitro, the engineered
tissue when implanted may reform, refunction, or replace the pathological tissue.
Specifically, vascular tissue engineering can be divided into microvascular and
macrovascular engineering.

Microvascular tissue engineering tries to recreate

microvessels (~ < 200µm in diameter) such as arterioles, capillaries, and venules utilizing
sourced endothelial, stem, or heterogenous cell populations grown within a matrix that
supports proliferation, differentiation, and angiogenesis. That matrix can be proteinaceous
mixtures resembling endogenous extracellular matrix, non-proteinaceous complexes
forming what are called hydrogels that are highly viscous for mechanical rigidity and
structure, or finally hybrids of protein and non-protein complexes. The most common
biomaterials used include alginates51, agarose52, collagen and fibrin53, methacrylated
gelatin (GelMA)54, and poly (ethylene glycol) dimethacrylate (PEGDMA)55.
A common misconception within the bioengineering community is that these
matrices are commonly referred to as ‘scaffolds’, suggesting that they only provide
mechanical integrity and structure in an intended 3D orientation, however, they must also
provide a microenvironment that can allow for cell-to-cell communication, chemotactic
signaling, nutrient diffusion, porosity for cell migration, binding sites for cell adhesion,
induction of intracellular signaling driving angiogenesis and growth, and finally, upon
implantation, biocompatibility with host tissue leading to functional reperfusion and/or
replacement of pathologic tissue. Therefore, it is safe to assume that the use of the term
‘scaffold’, when referring to microvascular engineering, from this point forward
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encompasses the entire components necessary, devoid of cells, both biological and nonbiological, to form microvessels in vitro.
There are two general theories regarding the bioengineering of microvessels. The
first is the utilization of techniques such as sterolithography, laser etching, or creation of
molds to produce specific channel geometries resembling capillary beds onto a gel or
plastic substrate, and secondarily addition of endothelial or other cells to line the
aforementioned channels. This process is known as microvessel patterning and was first
developed by Tien and colleagues in the early 2000’s56,57. Zheng and colleagues utilized
such a technique to create a patterned stamp which imprinted in collagen hydrogels and
subsequent sandwiching of hydrogels led to the formation of hollow tubes which were then
seeded with human umbilical vein endothelial cells (HUVECs)58.

Similarly, ‘negative

molds’ where created as well by the Tien group using polymers such as pluronic that can
undergo phase change and allow removal at specific temperatures leaving channels
behind59. Pre-patterning using molds or etchings create microarchitectures for endothelial
cells to line, artificially producing specific geometric tubes of endothelium. Interestingly,
using pre-patterning, hemodynamic stresses can be calculated precisely, thus limiting
unknown shear effects on endothelial tubes post formation when exposed to flow.
However, there are several drawbacks using these techniques which include 1)
difficulty creating channels less than 50µm in diameter, 2) assuming pre-patterned channel
architectures are necessary to create microvessels that will retain structure, recapitulate
native microvessels, and undergo appropriate inosculation without extensive pruning or
loss of vessel mass upon implantation, and 3) using highly modified plastics and hydrogels
that are not FDA approved for medical device implants. Indeed, pre-patterning can limit
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biological derived movement of cells via chemotaxis, and when only seeded with
endothelial cells, ‘man-made microvessels’ do not recapitulate native microvasculature60.
While in vitro experiments may benefit from utilizing these systems, they are insufficient
to create implantable microvessel rich tissue for therapeutic applications61.
The second theory for the bioengineering of microvessels sources heterogenous cell
populations grown in a biologically derived, 3D extracellular matrix exposed to certain
growth factors promoting formation of microvessels that more closely resembles
vasculogenesis and angiogenesis in vivo. Indeed, in native tissue there are complex
interwoven stimuli that act both locally and systemically in order for functional
microvasculature production. Autocrine and paracrine growth factors and cytokines dictate
chemical gradients driving endothelial cell sprouting and motility.

Additionally,

mechanical constraints and physical space play a huge role as both a barrier and a stimulus
to allow for coordinated guidance and microvascular position and alignment62-64. For
example, the presence of extracellular matrix proteins collagen IV, collagen VIII and
laminin help establish cell polarity and restriction and are the main components of the
underlying basement membrane65,66. However, extravascular space collagen type I and
fibrin have demonstrated robust angiogenesis possibly due to integrin specific binding and
activation on EC membranes, as well as respond to MMPs in order to degrade and remodel
fibrils for endothelial cell migration, as well as retention of soluble growth factors such as
VEGF and bFGF63,67. Both the extracellular matrix and the paracrine and autocrine
signaling it supports allows for the formation of a stable heterogeneic microcirculation to
develop, in other words, vessel caliber and diameter can vary allowing the expansion,
production, pruning, and remission of microvessels to encompass arterioles, capillaries,
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and venules, a system not supported in the aforementioned pre-patterned micro-etching
standards for bioengineering.
Additionally, endothelial and other cells not only experience contact inhibition via
active grouping and coupling between cells, but also through mechano-chemical coupling
which can be described as stresses and tensions cells provide to their microenvironment
through focal adhesion kinases, and also through mechanical compression and tension that
the local microenvironment can play on the cell as well68-70. Specifically, these forces can
maintain endothelial cell shape as well as cell alignment which can determine capillary bed
3D microarchitecture within tissues71-73. This interplay is crucial such that mechanical
barriers provided within ECM must be broken down and remodeled to allow for sprout
formation in angiogenesis and subsequent tip cell motility and migration via secretion of
matrix metallo-proteases.
Our group and others focus on production of bioengineered microvessels utilizing
predominantly 3D endogenous ECM systems encompassing adipose-derived stromal
vascular fraction cells (SVF) as the cell population necessary to reform microcirculation in
vitro, the composition of which will be described in detail further.
Macrovascular engineering refers to the production of blood vessel mimics usually
greater than 1 mm in diameter in the hopes of replacing diseased arteries and veins. Large
vessel prosthesis currently approved for clinical use for vessel grafting greater than 6mm
in diameter are predominantly made of materials such as polyethylene terephthalate
(PTFE) also known as Dacronâ. Dacron was first discovered in 1941 by Whinfield whom
was developing the polymer as polyester film Mylatâ for DuPont. It was adapted for
medical use in the 1950s when West and colleagues utilized tube formations of woven
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PTFE to treat arteriosclerotic occlusions of the femoral artery74. Dacron to this day is used
clinically in cases of femoral artery repair, aortic aneurisms and resections, and large vessel
substitutes surgically. However, its use is limited for smaller artery and vein anastomoses
because if the diameter is less than 6mm, thrombosis and occlusion predominate and can
halt physiologic blood flow. As such, currently there are still no artificial coronary artery
substitutes approved by the FDA for CABG. There has been a recent push by the
bioengineering community to produce blood vessel mimics utilizing multiple methods,
including but not limited to cell-sheet rolling and electrospinning tubular scaffolds that
may or may not be cellularized ex vivo.
The first to describe the process of electrospinning a biodegradable nanofibrous
structure for a blood vessel mimic was Ramakrishna and colleagues in 2003.
Electrospinning is a fiber production method in which electric force is utilized to draw
threads from liquefied polymer solutions onto a rotating, grounded mandrel. Specifically,
once the liquid droplet exiting the needle becomes sufficiently charged, electrostatic
repulsion occurs and is greater than the surface tension of the tip of the dispenser. The
droplet subsequently becomes stretched and exudes in what is called the ‘Taylor cone.’
The volatile solvent evaporates and the fibrous polymer deposits in random orientation in
nanometer sized fibers onto a grounded collector. Ramakrishna and colleagues were the
first to describe the use of the biodegradable polymer poly(L-lactid-co-e-caprolactone
[P(LLA-CL)] to electrospin BVMs. In their experiments they claimed that the alignment
of the deposited fibers (~ 500nm in diameter) where in such a manner that they mimicked
circumferential orientation of cells and fibrils around the medial layer of a native artery.
They indeed cultured large vessel derived smooth muscle cells onto the electrospun
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scaffold to note cell attachment, growth and alignment. They concluded that the cells
attached and aligned in the orientation of the deposited electrospun fibers and as such
provided a favorable morphology to produce blood vessel mimics in the future75. While
these early experiments did not produce vessel mimics resembling native arteries or veins,
they provided a foundation in order to study electrospinning and cell sodding methods
further.
Many others went on to study electrospinning using solutions containing additional
biodegradable plastics as well as mixtures with extracellular matrix proteins such as
collagen and elastin in the hopes of increased retention and cell binding to native ligands76.
Cell sheet engineering creating monolayers of cells in vitro, then subsequently rolling them
onto electrospun tubes is an additional method studied for bioengineering BVMs. Ahn et
al. described creating a smooth muscle cell sheet one layer thick, which was removed from
culture via a thermosensitive poly(N-isopropylacrylamide) coated culture dish, hand rolled
onto polycaprolactone (PCL) electrospun tubes, and placed in a pulsatile flow bioreactor.
They concluded that the cells retained tight junctions with one another, were able to
infiltrate into the electrospun scaffold, and had increased viability due to pulsatile flow
over non-flow and non-cell-sheet controls77. While most of the early studies utilized
smooth muscle cells as the cell population of choice to line electrospun grafts78,79, our
group and others studied stromal vascular fraction cells as potential endothelial precursors
for graft lining and large blood vessel tissue production80-82.
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The Stromal Vascular Fraction
Stromal Vascular Fraction is a dynamic, complex group of cells that can be derived
from adipose tissue depots in both humans and other mammals. It was discovered as a
potential therapeutic cell source to form fully functional vascularized tissue by Wagner and
Mathews in the 1970s, whom adopted the use of collagenase to digest tissues to release
cellular components as previously described by Rodbell83. The enzymatic digestion of fat
tissue allowed for the production and separation of tissue components via centrifugation,
ultimately providing the ability to isolate buoyant adipocytes and dense cellular pellets, the
latter of which would be described as stromal vascular fraction. Within this dense cellular
pellet there are a multitude of cell types including endothelial cells, smooth muscle cells,
fibroblasts, pericytes, perivascular cells, immune cells, adipose stem cells, and
mesenchymal stem cells84-88.
The analysis of lipoaspirate-derived SVF was first described by Williams and
colleagues where they state that of the cells left intact after collagenase digestion, seventyfive percent expressed von Willebrand factor (vWF) while almost six percent expressed
alpha smooth muscle actin, and seventy-four percent expressed EN4, a specific antigen
found on endothelial cells86. Indeed, other groups went on to characterize the cell types
found in both freshly isolated stromal vascular fraction and passaged cultures. More
specifically, it was noted that freshly isolated SVF had a relatively low number of stromal
cells as characterized by markers CD13, CD29, CD44, CD63, CD73, CD90, and CD166,
however these cells seemed to proliferate rapidly during successive passages. More
interestingly, endothelial cell markers such as CD31, CD144, VE-cadherin, vascular
endothelial growth factor receptor 2 (VEGFR2), and vWF were not changed significantly
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during cell culture and passage89. These data suggested that freshly isolated SVF could be
a source of endothelial cells and perivascular cells, which may have therapeutic potential
for re-vascularizing tissues.
However, there is discrepancy between groups characterizing the proportions of
each cell type found in SVF. This can be attributed to experimental variability in which
adipose isolation sites are different, enzymes used for digestion are different, and patients’
wide variability in comorbidities and unknown pathologies. Our group more recently has
characterized rodent SVF cells through fluorescence-activated cell sorting at freshly
isolated time points as well as post culturing. Interestingly 33% of the freshly isolated SVF
cells were endothelial cells which reduced to just 10% of the total population after culture
and passage. CD14+ monocytes and macrophages declined from 22% to 18%, ckit+
progenitor cells declined from 5% to 1% and PDGFR-B+ perivascular cells declined from
20% to 18%90. These data along with others undoubtedly demonstrates the vast variety in
SVF cell composition, but maybe more importantly, culturing and expansion can greatly
vary the cell type and differentiation status of sub populations of cells found within SVF.
Freshly isolated SVF as such may have greater consistency and more vasculogenic
potential due to higher amounts of endothelial and perivascular cells at the time of isolation.
In addition, freshly isolated SVF is arguably a more clinically viable cell product due to its
minimal manipulation which may translate at the bedside.
While composition may vary, endothelial cell function within SVF seems to
remain.

Monsuur and colleagues went on to study the properties of SVF-derived

endothelial cells to compare with other endogenous endothelial cells, more specifically,
dermal endothelium. They characterized endothelial cells isolated from adipose-derived
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SVF and from the dermis. Indeed, both populations expressed the typical endothelial
markers PECAM-1, ECAM-1, Endoglin, VE-cadherin and VEGFR291. They concluded
there were vast similarities between the two endothelial cultures and the ability of SVFderived endothelial cells to respond to bFGF and VEGF was similar to that of dermal
endothelial cells91. SVF may be an excellent source of endothelium for tissue engineering,
due to its abundance and relative ease of isolation. These early in vitro experiments
provided an amalgam of data necessary to continue studies on SVF for regenerative
vascular therapeutics.
SVF can undergo angiogenesis and spontaneously self-assemble into vascular
networks when grown in vitro67,84,85. If we look at our own vascular tree within our bodies,
we notice that blood vessels are hierarchical giving off branches with changing diameters
of the lumen to facilitate nutrient and waste exchange at the single cell level, all the way
down to capillaries92. This structure is required for function, where larger more smooth
muscle containing vessels, resistance vessels, dictate flow of oxygenated blood, and
smaller, mostly endothelial only vessels dictate nutrient exchange27. The unique properties
of SVF demonstrate these phenomena after vasculogenesis and angiogenesis, even when
cultured in vitro. Koh and colleges found that the endothelial cells within SVF are
imperative to form microvascular structures in vitro, and their depletion destroys any
phenotypic reorganization85. However, if only endothelial cells are used in culture, while
tube-like structures do occur, these immature microvessels are uniform in diameter and do
not approximate endogenous vasculature. As aforementioned, SVF contains perivascular
cells, endothelial cells, adipose stem cells, as well as many other cell types. Focusing on a
two-cell system, Merfeld-Clauss and others isolated adipose stem cells as well as
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endothelial cells from SVF to co-culture in order to understand signaling and
differentiation effects the two cell populations may have upon one another in vitro.
Interestingly, experimental groups in which both cell populations were cultured together
yielded the highest degree of diverse endothelial network formation. Adipose stem cells
took on a slight smooth-muscle cell phenotype with increased alpha smooth muscle actin
expression while endothelial cells increased expression of CD3193. This interplay between
perivascular support cells, stem cells, and endothelial cells is critical to form
microvasculature both in vitro and in vivo, especially microvasculature that resembles
native host vasculature. SVF as a heterotypic cell population is unique in that it contains
all the cells necessary to reform hierarchical vasculature including but not limited to
smooth muscle cells, pericytes, endothelial cells, and stem cells. SVF affords an easily
harvested cell population with potential for regenerative vascular therapeutics94.
SVF also forms fully functional, perfusable microvasculature when implanted in
vivo66,95. More specifically, retained microvessel fragements isolated from adipose tissue
retain angiogenic capacity when implanted in vivo in a three-dimensional collagen gel.
Within the first 5 days of culture, rat microvascular fragments undergo angiogenic
sprouting; these “activated” fragments will then seek out endogenous microvasculature and
inosculate, in order to allow blood flow through the lumens of host vasculature and newly
implanted vasculature.

Post inosculation, implanted SVF-derived microvasculature

undergoes phenotypic remodeling and functional response to blood flow and shear stress
and can differentiate into a full range of vessel types including arteries, arterioles,
capillaries, venules, and veins95.
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Due to the neovascularization capacity of SVF both in vitro and in vivo, many
groups have sought after means to automate cell isolation for application in a clinical
setting. As an example, post minimally invasive surgery, lipoaspiration can be delivered
to the tissue genesis incorporated, TGI 1000 Cell Isolation SystemTM, that has a fully
enclosed loop where contamination and personnel handling are at a minimum. In a study
utilizing lipoaspirate from patients, the TGI instrument yielded 1x105 SVF cells per cc of
fat with endotoxin levels below FDA recognized standards. Cells were subsequently
sodded on expanded polytetrafluoroethylene peripheral vascular bypass grafts and reimplanted into 7 patients yielding 60% patency post 1 year implant96. Many other groups
have also developed similar systems with positive results of cell isolation with no
contamination and variable yields of total cells from lipoaspirate80,97-102.
SVF has been used clinically to treat a variety of diseases. The highest clinical
usage in terms of patients treated with SVF cells are mostly for degenerative cartilage
diseases such as osteoarthritis, where SVF are reinjected into the inflamed site and
modulate inflammation as well as stimulate regenerating chondrocytes103-107. The presence
of adipose stem cells and mesenchymal stem cells within SVF potentially allows for
differentiation into tissues of multiple lineages, which may have therapeutic potential for
treatment of degenerative diseases where multiple tissue types are involved. Zuk et al. were
the first to demonstrate that processed lipoaspirate could differentiate under certain growth
conditions to cells of osteogenic, adipogenic, chondrogenic, and myogenic lineages108.
Adipose derived stromal vascular fraction has been utilized clinically whether through
clinical trials or individual cases as cellular injections for breast augmentation109-111,
craniofacial

defects110,112-114,

fibrosis115,

irradiation
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Crohn’s

disease116-121,

and

multiple/systemic sclerosis122. While the heterogeneity as well as variability between SVF
samples does not help to elucidate specific mechanisms involved, osteoarthritic patients
have seen positive changes in flexion and extension capacities as well as reduced pain and
inflammation over no cell controls104. SVF as a tissue source has generated a lot of hype
in the field of regenerative medicine, however additional studies are necessary to elucidate
specific mechanisms in play.
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SIGNIFICANCE AND RESEARCH PLAN

Myocardial infarction due to ischemic injury is the leading cause of congestive heart failure
and subsequent death in the United States123. There has been a significant amount of research to
produce therapies to mitigate ventricular wall remodeling, fibrosis, and dilation. Many therapies
include the use of acellular hydrogel materials injected into ischemic myocardium to provide
mechanical support, cellular populations including differentiated or non-differentiated stem cells
injected to produce viable myocytes, or epicardial wraps made of cellularized and non-cellularized
sheets to provide external mechanical and cellular support. These therapeutic strategies are
different in approach and have varying efficacies including rates of cellular and material retention
and improvement in cardiac function. It is possible that the underlying pathology is not being
addressed with many of the injectable therapies or external wraps and needs to be further assessed.
Damaged myocardium due to ischemic injury from coronary occlusion requires
reperfusion and retention of functional microvasculature to mitigate damage at the cellular level of
the infarct. Ventricular necrosis and fibrosis are directly correlative to the loss of blood supply and
subsequent nutrient delivery to starved myocardium. As such, restorative microvascular perfusion
could alleviate cellular damage that ensues post myocardial infarction. Stromal vascular fraction
(SVF) is a dynamic mixture of endothelial cells, smooth muscle cells, pericytes, adipocyte
progenitors, immune cells, fibroblasts, stromal cells, as well as unidentified circulating progenitor
cells. This complex yet relatively abundant cell population has successfully been differentiated
into multiple cell types including adipocytes, osteoblasts, chondrocytes, pericytes and myocyctes
under certain conditions. Adipose derived stromal vascular fraction has also been implemented in
multiple clinical trials for regenerative medicine. However, vascular self-assembly or
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neovascularization from SVF in vitro as an implantable model is not fully understood. Our lab and
others have studied the effects of SVF and microvascular network formation both in vivo and in
vitro. Currently, the recapitulation and ability of SVF to form microvascular networks in vitro
depends on certain medias and growth factors that cannot be used in a clinical implantation model.
However, SVF when injected with extracellular matrix components, as a heterogeneous cellular
mileu, can form functional microvasculature in vivo.

We hope to understand and recreate

functional microcirculation utilizing SVF in an in vitro system, that after maturation can be
implanted along with a tissue engineered conduit vessel to provide reperfusion to ischemic tissues.
It is imperative to provide a functional microcirculation for tissue that is implanted or starved of
blood flow in regenerative medicine. It is hypothesized, and a long-term goal for these studies
is that a tissue engineered macro and microcirculation can be anastamosed to endogenous
vasculature and provide reperfusion to damaged tissues and mitigate the pathogenesis
involved in diseases such as myocardial infarction.

Specific Aim 1:

Determine the mechanism by which SVF forms neovascular networks in

3D fibrin gels in vitro. SVF can undergo vasculogenesis and produce neovasculature in two
dimensions (2D) in vitro, utilizing commercially available Matrigelâ, a heterogenous biomaterial
made up of multiple extracellular matrix (ECM) proteins produced from Engelbreth-Holm-Swarm
mouse sarcoma cells. SVF as well as endothelial pure cell populations have been able to form
patent tubular networks on Matrigelâ-coated in vitro models, however, Matrigelâ is not a
clinically relevant or translatable biomaterial. Thus, it is imperative to explore other biomaterials
and hydrogels as a means for clinical implementation. Our group has shown that intact isolated
microvessel fragments, obtained from human adipose tissue, can be cultured in three dimensional
(3D) polymerized type I collagen gels and undergo angiogenesis as well as inosculation events with
other sprouting microvessels in vitro; and when implanted in vivo, inosculation between host and
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implant allows for a functional microcirculation to develop67. It can be argued that in order for
mature functional neovessels to form in vitro as well as in vivo, the entire cellular milieu composing
the microcirculation (arterioles, capillaries, venules) must be present; including endothelial cells,
smooth muscle cells, pericytes and associated immune and stromal cells. However, SVF digested
longer than 35 minutes to release individual cells from one another, and devoid of microvascular
fragments, can form microvascular networks in 3D fibrin but not 3D collagen I in vitro over a 7day culture period.

Hypothesis 1: Specific ECM proteins are required to guide and stimulate SVF EC to
undergo vasculogenesis, which is dependent upon the binding and activation of the
fibrin-specific integrins 𝛼v𝛽3 and 𝛼5𝛽1 and not collagen specific integrins. Activation of
fibrin specific integrins promotes angiogenic events on endothelial cells within SVF to
hyper-stimulate endothelial tube formation and perivascular recruitment within 3D fibrin
in vitro systems.

Specific Aim 2: Create deliverable tissue units of SVF-derived microvasculature or
macrovasculature utilizing bioprinting, and electrospinning technologies. Our group
and others have successfully created 3D implants utilizing microvessels derived from
adipose tissue and collagen I gels, however, these approaches require manipulation and
handling that does not afford clinical translatability. As such, it is necessary to discover
techniques with minimal manipulation, and high automation to create tissue units using
SVF for implantation in a clinical setting.
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Hypothesis 2: Microvessel tissue units created via SVF embedded in either fibrin or
collagen I gels can be bioprinted into discreet dosage units with minimal manipulation
and handling for therapeutic purposes. Macrovessel structures can also be created
utilizing electrospinning technologies, however, specific porosities within electrospun
conduits are necessary to allow for adequate cellular infiltration and retention in vitro.
Correct dosing of cells may be imperative to restore reperfusion in ischemic tissues, as well
as retain cells at sites of implantation. It is possible that mature microvascular units
contained within 3D ECM may provide more therapeutic relevance than individual cells
suspended in solution for injection. Discreet microvessel-rich tissue units with known
concentrations of cells can thusly be produced in a format that does not create zones of
ischemia or necrotic cores in vitro. Macrovascular structures as well can be produced
utilizing SVF, however cellular retention under physiological flow is imperative for graft
success. Cellular retention may be modified by creating porosities relevant for cellular
infiltration and migration in an in vitro setting.
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CHAPTER II
STROMAL VASCULAR FRACTION FORMS DENSE MICROVASCULAR
NETWORKS IN 3D FIBRIN BUT NOT 3D COLLAGEN I

An Automated In Vitro Assay to Determine Vasculogenesis and Angiogenesis of SVF
Cell Populations

Introduction
Tissue engineering the microvasculature is a novel approach towards therapeutic
reperfusion for ischemic disease states such as peripheral vascular disease and acute
myocardial infarction124-130.

Microvascular engineering requires both cellular and

extracellular components to recapitulate the microenvironment and tissue organization of
endogenous microcirculation.

Indeed, many researchers have isolated vascular

components from a variety of tissues including endothelial-only populations from both
large vessel (human umbilical vein and other large adult vessels) and microvascular
tissues131-133.

In vitro studies have established the ability of these endothelial cells to

undergo the formation of tube-like structures, a process that is highly dependent on the
extracellular matrix used as a substrate134.
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Additionally, adipose derived stromal vascular fraction cells (SVF) have been
proposed as a source of cells for microvascular tissue engineering23,84,135,136. Adipose
derived SVF represents a heterogeneous cell population

137,138

that has demonstrated

efficacy in the formation of functional microcirculation following implantation92,139-141.
These in vivo studies are based, in part, on the observed ability of SVF-derived, cultured,
microvascular endothelial cells to undergo tube formation in vitro134; however, and the
impetus for the studies reported here, the in vitro formation of tube-like structures by
freshly isolated, heterogenenous SVF cell populations has not been reported.
Previous in vitro “angiogenesis” assays have utilized endothelial cell cultures
placed on collagen type IV or Matrigelâ-treated culture surfaces with a temporal sequence
of tube-like structure formation that occurs within 24 hours of plating134,142-144. It can be
argued that this self-assembly of cells into tube-like structures does not recapitulate the
process known as angiogenesis (i.e. formation of new vessels from pre-existing vessel) and
recapitulates only one part of the vasculogenic process (i.e. formation of blood vessels from
cellular components).

The current studies are based on preliminary observations that

freshly isolated adipose-derived SVF cell populations do not undergo tube-like structure
formation in the first 24 hours after plating on Matrigelâ. However, extending the
assessment of the adipose SVF cell populations plated on Matrigelâ for a 7-day period
resulted in the observation of cell aggregation, tip cell formation, sprouting of vascular
structures followed by branching and inosculation. Herein, we describe an in vitro assay
that we propose captures each step of vasculogenesis and angiogenesis over a 7-day period
via time-lapse microscopy utilizing rat epididymal fat or human lipoaspirate derived SVF
as a cell source.
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Materials and Methods
Animals and Ethics Statement
All animal procedures were conducted in compliance with University of Louisville
School of Medicine IACUC-approved protocols and NIH guidelines. Isoflurane gas was
administered for anesthesia.
SVF Isolation from Sprague Dawley Rats
Rat epididymal fat pads were excised from 6 to 8-month-old Sprague Dawley rats
at weights greater than 250g under sterile surgical procedure and isoflurane anesthesia. All
procedures were reviewed and approved under the University of Louisville’s Institutional
Animal Care and Use Committee. Excised fat pads were placed in PBS containing 0.1%
bovine serum albumin (Sigma Aldrich, St. Louis MO) and kept at 4°C for 15 min prior to
digestion. Samples were washed with BSA-PBS and minced for 2 min until particulates
could pass through a 50mL aspirating pipette. 2mg of Type I Collagenase (Worthington
Biochemical Corporation, Lakewood NJ) was added per mL of fat, aliquoted at 20mL total
volume in 50mL conical centrifuge tubes, and rotated in an Envirogenie Incubator
(Scientific Industries, Bohemia, NY) at 35 rpm and 37°C for 35 min. Samples were
pelleted via centrifugation at 350xg for 4 min at RT. Buoyant adipocytes were aspirated
and discarded, and dense cellular pellets were suspended and washed one time in BSAPBS. Samples were re-centrifuged for 4 min at 350xg. The SVF pellet was filtered through
a 250µm mesh filter (Tissue Genesis Incorporated, Honolulu HA) and collected into
DMEM containing endothelial cell growth supplement, 2mM L-glutamine, 10% fetal
bovine serum, and 5mM Hepes buffer. Samples were kept at RT prior to plating.

35

SVF Isolation from Human Lipoaspirate
Human lipoaspirate was digested under sterile conditions following the same
protocol as rat SVF isolation. Lipoaspirate was not minced however, and Worthington
Collagenase Type I was added to obtain a final concentration of 6mg/mL collagenase to
fat volume. The SVF pellet was resuspended in M199 media containing endothelial cell
growth supplement, 10% fetal bovine serum, 2mM L-glutamine, 5mM Hepes buffer.
Angiogenesis Assay and Image Capture
Either 500µL of growth factor reduced Matrigelâ (Corning, Corning NY),
5mg/mL bovine fibrin (Sigma, St. Louis MO), 3mg/mL rat tail collagen (Corning, Corning
NY), 1% porcine gelatin (Sigma, St. Louis MO), or 2µg Laminin 332 (Abcam, Cambridge
MA) was added to each well of a 48 well polystyrene cell culture plate (Corning, Corning
NY) at 4°C. Fibrin was polymerized through thrombin activation at 2U/mg fibrinogen.
Collagen was polymerized after the addition of 4N NaOH to a pH of 7.7 and incubation at
37°C. The Matrigelâ, fibrin, and collagen hydrogels solidified after 15 min of incubation
at 37°C. 1.6 x 105 SVF cells were subsequently plated per well and allowed to adhere to
the ECM overnight in a tissue culture incubator (37°C, 5% CO2). Media was changed the
following day and the 48 well plates were loaded into a Cytation 5 cell imaging multimode reader (Biotek, Winooski VT) set to 37°C and 5% CO2. A time lapse capture
experiment was created in Gen 5 software utilizing a 4X objective capturing phase contrast
images at 15 min intervals with an endpoint of 160h. Media was changed every other day.
Specific inhibitors of angiogenesis were added at 25µM or 1µM at each media change over
the 160h incubation time. Inhibitors included Imatinib mesylate (1µM) (Sigma Aldrich,
St. Louis, MO), DAPT (25µM) (Abcam, Cambridge, UK), ZM 306416 (25µM)
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(Selleckchem, Houston, TX), and ATN 161 (25µM) (Peptides International, Louisville,
KY).
Image files were stitched together using ImageJ software. Individual still images
were selected at remarkable time points to demonstrate events such as clustering (18h), tip
cell formation (36h), stalk cell formation (60h) and inosculation (112h). SVF and huvec
cells grown on Matrigelâ to the 112h endpoint were fixed with 4% paraformaldehyde for
15 min at RT, permeabilized with 0.1% Triton X 100 for 15 min at RT and stained with
griffonia simplicifolia 1 lectin conjugated to FITC (1:500) (Vector Biotechnologies,
Burlingame, CA) and a-smooth muscle actin mouse monoclonal primary antibody (1:500)
(Santa Cruz Biotechnology, Dallas, TX) overnight at 4°C to visualize endothelial and
smooth muscle cells respectively.
Event Counting and Statistical Analysis
Cell clusters were automatically counted using Gen 5 software under cellular
analysis tools with threshold intensities set at values less than 10,000, minimum object size
set at 25µm and maximum object size set at 1mm. These counts along with manual counts
of tip cells and stalk cells were taken using still frames at 18h, 36h, 60h, and 112h
respectively of both control and treated groups. Graphs and statistics were run with
GraphPad Prism v.7 Software (La Jolla, CA). P values were calculated via one-way
ANOVAs with means and standard deviations plotted per group as compared to vehicle
only (control group).
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Results
SVF grown on fibrin, collagen, gelatin, and laminin extracellular matrices behave
differently than SVF on Matrigelâ. Cells form monolayers on the aforementioned ECM,
whereas SVF grown on Matrigelâ undergoes phenotypic change resembling
vasculogenesis and angiogenesis after 112h (Figure 1). Subpopulations of SVF cells
plated on Matrigelâ begin to migrate and form clusters ranging in size and cell number
after 18h of incubation (Figure 2A, B). These clustering events resemble angioblasts
forming blood islands, the initial steps of vasculogenesis in the embryo.

The next

phenomenon occurs when tip cells subsequently migrate away from the cluster around 36
hours of incubation (Figure 2C, D). During angiogenesis, endothelial cells emerge from
a preexisting vessel and remodel surrounding ECM via matrix metalloprotease secretion.
Ultimately, these tip cells migrate away from the nascent vessel along with additional
endothelial cells creating collateral vessels that will form lumens over time. Tip cells must
have additional endothelial cells migrate behind them to properly signal growth and
proliferation events away from the nascent vessel. These specific endothelial cells are
termed stalk cells in angiogenesis.
Indeed, after tip cell migration, we see the development of stalk cells growing out
of the cluster at 60h of incubation as demonstrated in figure 2E, F. Stalk cells signal
adjacent tip cells through the NOTCH pathway to maintain tip phenotype as well as
maintain stalk phenotype.

Briefly, VEGF-A signaling through VEGFR-2 causes an

upregulation of delta-like ligand 4 which subsequently binds Notch to facilitate receptor
cleavage by g-secretase. Soluble notch can then translocate to the nucleus and cause
downstream transcriptional activation; including the up regulation of VEGFR-1, a receptor
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with low signaling activity via the VEGF-A ligand. VEGFR-2 is downregulated while
VEGFR-1 is upregulated on stalk cells, promoting the stalk cell phenotype.
After 60h of incubation and up to the endpoint of 112h we see the retention of stalk
cells as well as tip cell migration and ultimately increased vessel density and complexity
including branch-points and inosculation events as demonstrated in figure 2G, H. To
validate that the neovasculature was comprised primarily of the endothelial cell population
within SVF, cultures incubated to 112h were stained with griffonia simplicifolia 1, an
isolectin that binds endothelial cell specific glycoproteins and widely used in the field as a
rat endothelial cell marker. Figure 3 demonstrates that both on gelatin and Matrigelâ
there is a predominance of endothelial cells, however, only on Matrigelâ do GS1-positive
tip cell and stalk cell phenotypes form.
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Figure 1: 4X phase contrast images of SVF grown on 3 mg/mL collagen I (A), 1% gelatin
(B), Matrigelâ (C), 5 mg/mL fibrin (D), or 2 µg laminin 332 (E) after 112h of incubation.
Monolayers of cells are formed on collagen I (A), gelatin (B) and laminin 332 (E) with cell
clustering demonstrated on Matrigelâ (C) and fibrin (D). SVF forms microvascular
networks on Matrigelâ (C).
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Figure 2: 4X phase contrast images of SVF grown on Matrigelâ at 18h (A, B), 36h (C,
D), 60h (E, F) and 112h (G, H). Images B, D, F and H are 3X optical zooms of boxed
sections of images A, C, E and G respectively. White arrows demonstrate initial cell
clustering occurring at 18h. Tip cell formation occurs at 36h as marked by the red arrow.
Stalk cell formation and elongation occurs at 60h as marked by the blue arrow. Branching
(green arrow) and inosculation (yellow arrow) can be seen at 118h in vitro.
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Figure 3: 10X fluorescent images of SVF grown on 1% gelatin (A) or Matrigelâ (B) for
112h. Blue: DAPI, Green: Griffonia simplicifolia 1 endothelial specific lectin-FITC,
Red: α smooth muscle actin-rhodamine.
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To determine if SVF was undergoing vasculogenesis and angiogenesis specifically,
the assay was repeated in the presence of the inhibitors DAPT, ZM 306416, Imatinib
mesylate, and ATN-161. DAPT is an inhibitor of the g-secretase that cleaves notch
receptor to its soluble ligand preventing stalk cell phenotype. ZM 306416 is a small
molecule inhibitor of VEGFR-1145, again inhibiting stalk cell phenotype via the inhibition
of VEGFR-1. Imatinib mesylate blocks platelet derived growth factor receptor-b (PDGFRb)146 which is found on mural cells and instrumental in the recruitment of perivascular
support cells to developing endothelial tubes necessary for stabilization. ATN-161 is a
small molecule inhibitor of the a5b1 integrin147, a membrane bound protein that binds ECM
such as fibrin, fibronectin, and vitronectin (Figure 4). During the remarkable time points
(18h, 36h, 60h and 112h) data on cluster number, cluster size, the percentage of clusters
with tip cells, and the percentage of clusters with stalk cells were collected in the presence
of each inhibitor and compared to DMSO (vehicle only) control via one-way ANOVA.
Cluster number was significantly reduced in the presence of 25µM DAPT as well
as 1µM Imatinib mesylate at 36h as compared to DMSO controls (p < 0.05, p < 0.005
respectively, Figure 5A). It is possible that the biochemical pathways involved in stalk
cell formation as well as mural cell migration may play a role in the recruitment of
neighboring SVF cells during initial cell aggregation. In addition, a decreasing trend in
overall cluster number over time is noted, which can be explained by neighboring clusters
grouping together forming larger units, decreasing total counts. This phenomenon may be
due to a variety of cell-cell signaling promoting cell migration and interaction leading to
myofibroblastic contraction pulling groupings together. Indeed, myofibroblasts as well as
other contractile cells have been found in adipose-derived SVF148. Cluster size does not
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seem to change between inhibitor and non-inhibitor groups, however there is an increased
trend in average size of clusters over 112h across all groups (Figure 5 B).
While tip cell phenotype initially begins around 16h of incubation, certain clusters
retain tip cells even up until 112h of incubation. There is a significant reduction in tip cell
expression in the presence of Imatinib mesylate at 18h of incubation (p < 0.05) with a nonsignificant decrease in tip cells in the presence of the other angiogenic inhibitors. Again,
at 60h of incubation there is a significant decrease in tip cells in the presence of Imatinib
mesylate (p < 0.0005).
As tip cells migrate stalk cells form to stabilize and facilitate tip cell migration away
from clusters, up until tip cells inosculate with other microvessels, forming a neovascular
network. These events occur at 112h, where control groups begin to decrease tip cell
expression because of inosculation events, forming continuous vessel networks. However,
cells treated with DAPT have statistically higher amounts of tip cells as compared to
DMSO (p < 0.05). This retention of tip cells may be attributable to the loss of stalk cell
production via NOTCH pathway inhibition. Tip cells still can form and begin initial
migration away from clusters but cannot migrate more than a cell length away due to the
lack of stalk cell production. Tip cell percentage at 112h in the presence of Imatinib
mesylate is also significantly lower than the vehicle only group (p < 0.05, Figure 5C).
These data are corroborated with stalk cell counts at the significant time points. Indeed,
while tip cell percentage remains high in the presence of DAPT, and ZM 306416, stalk cell
percentages decrease significantly in the presence of ZM 306416 and Imatinib mesylate at
60h of incubation (Figure 5D).
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Figure 4: Schematic of SVF microvascular assembly on Matrigelâ in vitro. Digested SVF
cells (A) self-assemble into a cluster of cells by 18h (B). By 36 hours, endothelial cells
sprout out of the cluster with dendritic-like extensions (tip cells: orange ●) (C). DAPT, an
inhibitor of the g - secretase that cleaves notch to its soluble ligand, blocks tip cell signaling
to stalk cells, inhibiting stalk cell formation. Stalk cell formation occurs when notch
signaling leads to a higher expression of VEGR-1 on the adjacent cell. ZM 306416 blocks
VEGFR-1 and thus stalk cell phenotype. In the absence of inhibitors, stalk cells (black ✤)
migrate away from clusters behind tip cells by 60h (D). Microvascular networks continue
to grow after 112h and demonstrate increased complexity (E). Networks from adjacent
clusters inosculate with one another (yellow *) and recruit perivascular support cells to
endothelial tubes (purple ▲) (F). PDGFR-B is found on perivascular support cells and
activated by endothelial PDGF-β, which signals pericyte recruitment and tube
stabilization. Imatinib mesylate inhibits PDGFR-B.
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Figure 5: Number of SVF cell clusters (grouping of two or more cells over 25 µm in total
size) at 18h, 36h, 60h and 112h of incubation in the presence of inhibitors on MatrigelÒ
(A). Cluster size (µm) at 18h, 36h, 60h and 112h of incubation in the presence of inhibitors
(B). Percentage of clusters containing tip cells at 18h, 36h, 60h and 112h of incubation in
the presence of inhibitors (C). Percentage of clusters containing stalk cells at 18h, 36h,
60h and 112h of incubation in the presence of inhibitors (D). Angiogenic inhibitors (in
DMSO) were added at days 0, 2, 4, and 6. p < 0.05 *, p < 0.005 **, p < 0.0005 ***.
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Discussion
The formation of blood vessels in vivo occurs due to the processes of
vasculogenesis during development, and angiogenesis during development, pathologic,
and physiologic conditions.

The study of vasculogenesis and angiogenesis have been

aided by in vitro models that have utilized the ability to culture expand endothelial cells
and establish conditions that support the development of endothelial tube like-structures in
2D culture134,149,150. However, an in vitro model that recapitulates all vasculogenic and
angiogenic processes has not been established.
The formation of tube-like structures by endothelial cells plated onto extracellular
matrix has often been described as a model of angiogenesis in vitro but arguably this is not
accurate since only one of the processes necessary for angiogenesis occurs – tube
formation.

The results presented support the conclusion that adipose derived stromal

vascular fraction cell populations plated onto Matrigelâ, immediately after isolation,
exhibit both vasculogenic and angiogenic elements of microvessel formation.
The self-assembly of cells into microvessels requires the appropriate cells to
communicate with one another via paracrine and mechanical factors to promote
proliferation, migration and inosculation, ultimately forming functional microcirculation
from individualized cellular components151. Recapitulating this process in vitro requires
the presence of each cell type that makes up functional microcirculation, including but not
limited to endothelial cells, smooth muscle cells, pericytes and tissue resident immune
cells152. Adipose-derived SVF populations undergo vasculogenesis and angiogenesis as
demonstrated by events such as cell clustering, followed by tip cell formation, stalk cell
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formation, branching and ultimately complex network formation including the inosculation
of adjacent vessel projections.
These events can be validated by well-known inhibitors of angiogenesis, some
commonly used in the clinic as anti-angiogenic tumor pharmacotherapies. In the literature
as well as in our assay, DAPT, an inhibitor of the g-secretase that cleaves NOTCH to its
soluble ligand, prevents endothelial stalk cell formation and subsequent tip cell
migration40,41. ZM 306416, a small molecule competitive inhibitor of VEGFR-1 inhibits
stalk cell phenotype. Additionally, Imatinib mesylate, an inhibitor of PDGFR-B; a receptor
found on mural and perivascular support cells, prevents their recruitment to new
endothelial tubes via PDGF-b ligand chemotaxis. This PDGF axis is instrumental in the
mobilization and recruitment of stabilizing cells during angiogenesis, which ultimately
leads to retention of non-leaky, functional neovasculature50. These inhibitors validate the
vasculogenic and angiogenic processes occurring in this assay. However, the assay
provides the opportunity to validate and test a variety of pro or anti-angiogenic
pharmacotherapies.
Indeed, endothelial cell and mural cell self-assembly and proliferation is required
to form functional microvasculature, however, extracellular matrix (ECM) components are
necessary to stimulate cell growth and maturation153,154. Fully mature vascular networks
restructure surrounding ECM, via matrix metalloproteases, to create a distinct basement
membrane composed predominantly of type IV collagen and laminins 121 and 332;
allowing for appropriate adventitial cell signaling, structural integrity, and decreased
permeability155-157.

Matrigelâ, a complex mixture of extracellular matrix molecules

created from Engelbreth-Holm-Swarm Mouse Tumor, is an ECM derivative that contains

48

basement membrane proteins necessary to stimulate endothelial cells to migrate, proliferate
and create tube-like structure morphologies. As such, many in vitro angiogenesis assays
use Matrigelâ as the dominant ECM prior to cell plating. It is important to note that the
initial vascuolgenic and angiogenic events occur within the first 24 hours of cell plating on
substrates such as Matrigelâ for pure endothelial cell populations158.

This assay

establishes a methodology to evaluate and classify the vasculogenic/angiogenic capability
of patient specific SVF prior to clinical usage.
Although the current study represents a solely in vitro evaluation of vasculogenic
and angiogenic processes by adipose-derived SVF cell populations, the discussion of how
these results may relate to in vivo vasculogenesis and angiogenesis is warranted. Adiposederived SVF cell populations are under extensive study for use in clinical applications
where tissue revascularization is desired159. The direct injection of adipose derived SVF
cells into ischemic tissue has been hypothesized to support the formation of new blood
vessels in the target tissue. Most studies suggest the action of the SVF is to stimulate new
blood vessel formation by angiogenic mechanisms, that is by the formation of new vessels
from pre-existing vessels. Thus, the SVF cell population is providing a source of paracrine
factors. Pre-clinical studies provide an alternative explanation for increased vessel density
of SVF treated ischemic tissue. Using cell markers to evaluate the fate of injected adiposederived SVF, the cells exhibit the ability to self-assemble into new vessels. The new
vessels formed include arterioles, venules and capillaries and the cell tracking technology
indicates these new vessels originate from the injected SVF cell population92. However, it
remains unknown whether the injected SVF exhibit cell aggregation as observed in the
current in vitro system. We believe that SVF harbors the appropriate milieu of cells to re-
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form multi-cellular vascular components, including endothelial cells, smooth muscle cells,
pericytes, adipose derived stem cells as well as additional immune and stromal cells. The
development of this SVF-based automated assay of vasculogenesis may permit the
assessment of patient specific SVF cell populations to analyze vasculogenic and angiogenic
potential prior to surgical implantation.
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SVF cultured in 3D Fibrin and Collagen I; SVF Forms Robust Microvascular
Networks in Fibrin, Not Collagen I

Introduction
It is imperative to utilize biomaterials that can translate clinically when creating in
vitro tissue engineered constructs. For example, adipose-derived SVF, when digested to
recover microvessels, has shown potent angiogenesis in 3D collagen I in vitro and
inosculates with host microvasculature in vivo upon implantation67,84,95. However, little is
known about longer digests of SVF, leading to the recovery of discrete individualized cells
and subsequent culturing in 3D matrices in vitro. Previously, we demonstrated that SVF
forms microvascular networks on 2D Matrigelâ undergoing known angiogenic
mechanisms of cell clustering, tip cell formation, stalk cell formation, sprouting migration,
pericyte recruitment, and endothelial to endothelial inosculation, which can be mitigated
with inhibitors of the NOTCH pathway as well as the PDGF-B/PDGFR axis. However, it
was noted, while SVF formed tubular microvessel-like structures on 2D Matrigelâ, a nontranslatable ECM mixture, it coalesced into monolayers on 2D fibrin and 2D collagen I
instead160.
It is known that cellular behavior, including focal adhesion production, phenotypic
orientation, and migration are differentially activated when cells are embedded within 3D
matrices versus cultured on top of 2D substrates; which can be due to a variety of both
soluble factors and mechanical stimuli between cells and ECM69,73. As such, it seemed
necessary to study SVF behavior when embedded in clinically utilized biomaterials such
as fibrin and collagen I in order to create truly 3D implantable microvasculature.
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Interestingly, freshly isolated, filtered SVF forms robust microvascular networks in 3D
fibrin but not 3D collagen I over a period of 7 days. The aforementioned phenomena, while
highly dependent on cell type and microenvironment, can possibly be explained through
integrin binding and activation at higher densities in 3D cultures versus 2D cultures.
Endogenous extracellular matrix interacts with all cells via ligand binding at
integrin receptors. Integrins are transmembrane receptors necessary for cell-extracellular
matrix adhesion. They are made up of two subunits labelled alpha and beta which can be
differentially spliced to create multiple receptors with varying ligand bindings and
affinities. There are roughly 24 conformations of receptors that can bind to ECM proteins
including collagens, laminins, fibronectin, vitronectin, fibrinogen, ICAMs and VCAMS to
name a few. Specifically, of interest are the a1b1 and a2b1 integrins which bind to
extracellular collagen I and the a5b1 and aVb3 integrins which bind to fibrin. Integrins are
much more than just mediators of cell attachment to the surrounding ECM, they also
operate as signal transducers through the membrane and can modulate pathways including
phosphorylation and activation of multiple receptor tyrosine kinases that can subsequently
activate downstream cell proliferation, differentiation, survival, and apoptosis161,162.
In early experiments we embedded SVF cells (isolated from a 35min digest using
collagenase) in 3D fibrin or 3D collagen I and noticed robust microvascular formation in
fibrin but not collagen I through 7 days culture. Thusly, it was hypothesized that SVF
microvascular formation within a 3D substrate may be accelerated through vasculogenesis,
tubulogenesis, and angiogenesis if the integrins a5b1 and aVb3 were activated or
hyperactivated via fibrin binding.
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Initial studies by Soldi and colleagues demonstrated enhanced phosphorylation of
VEGFR2 when endothelial cells were plated onto ECM such as vitronectin and fibrinogen,
however, cells in suspension not plated with vitronectin or fibrinogen demonstrated
reduced VEGFR2 phosphorylation in response to VEGF. In addition, in the presence of
the anti-integrin aVb3 antibody, endothelial cells had inhibited phosphorylation of
VEGFR2 but not inhibited cell adhesion163. These studies singled out the integrin aVb3 as
the regulator of VEGFR2 signaling. The discoverers of the antibody against aVb3 were
Drake, Cheresh, and Little in 1995, where they noted that the antagonist LM609 inhibited
the formation of early quail embryo blood vessels via disruption of lumen formation as
well as fragmentation of ‘normal’ vascular patterning as described by fragmented aortae
and thin, poorly formed, lateral anastomotic vessels164.
aVb3 integrin also forms complexes with PDGFRb on perivascular cells165. In
additional studies by Ruoslahti and colleagues, CHO cells were engineered to overexpress
integrin subunits b3 or b1. Interestingly, there was increased activation of both VEGFR2
and PDGFRb only in the cells overexpressing integrin subunit b3. Additionally, mutants
of b3 with truncated cytoplasmic domains replaced by b1 cytoplasmic domains were still
able to phosphorylate both VEGFR2 and PDGFRb, suggesting that it is the activated
extracellular domain of integrin subunit b3 that is responsible for phosphorylation of
VEGFR2 and PDGFRb. In addition, the extracellular domain of integrin subunit b3 as well
as the subunit aV are necessary to phosphorylate VEGFR2, while only the extracellular
domain of the integrin subunit b3 is necessary to activate PDGFRb166.
Integrin aVb3 participates in both ‘outside in’ and ‘inside out’ signaling. In other
words, signals can be transduced via 1) ligand binding to extracellular domains, or 2)
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cytosolic kinases phosphorylating cytoplasmic domains167,168. As previously mentioned,
‘outside in’ signaling via endothelial cell adhesion to vitronectin and fibrin through integrin
aVb3, leads to phosphorylation of tyrosine residues Y747 and Y759 on the subunit b3.
‘Inside out’ signaling effectively refers to activation of VEGFR2 via VEGF binding, which
recruits cSrc to the cytoplasmic domain of integrin subunit b3, again phosphorylating
tyrosine residues Y747 an Y759 demonstrating redundancy and cross-talk between
VEGFR2-ligand complex activation of integrin aVb3, and integrin aVb3-ligand complex
activation of VEGFR2169.
Many have studied tissue engineering of microvessels in both 3D fibrin and 3D
collagen I using a variety of endothelial cell sources for neovascularization128,170,171.
However, herein we describe robust neovascularization of 3D tissue constructs, utilizing
adipose-derived SVF cultured in 3D fibrin and 3D collagen I over 7 days. SVF forms
robust microvascular networks via known angiogenic mechanisms in fibrin in a VEGF and
an integrin aVb3 dependent manner.
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Materials and Methods
Animals and Ethics Statement
All animal procedures were conducted in compliance with University of Louisville
School of Medicine IACUC-approved protocols and NIH guidelines. Isoflurane gas was
administered for anesthesia.
SVF Isolation from Sprague Dawley Rats
Rat epididymal fat pads were excised from 6 to 8-month-old Sprague Dawley rats
at weights greater than 250g under sterile surgical procedure and isoflurane anesthesia. All
procedures were reviewed and approved under the University of Louisville’s Institutional
Animal Care and Use Committee. Excised fat pads were placed in PBS containing 0.1%
bovine serum albumin (Sigma Aldrich, St. Louis, MO) and kept at 4°C for 15 min prior to
digestion. Samples were washed with BSA-PBS and minced for 2 min until particulates
could pass through a 50mL aspirating pipette. 2mg of Type I Collagenase (Worthington
Biochemical Corporation, Lakewood, NJ) was added per mL of fat, aliquoted at 20mL total
volume in 50mL conical centrifuge tubes, and rotated in an Envirogenie Incubator
(Scientific Industries, Bohemia, NY) at 35 rpm and 37°C for 35 min. Samples were
pelleted via centrifugation at 350xg for 4 min at RT. Buoyant adipocytes were aspirated
and discarded, and dense cellular pellets were suspended and washed one time in BSAPBS. Samples were re-centrifuged for 4 min at 350xg. The SVF pellet was filtered through
a 250µm mesh filter (Tissue Genesis Incorporated, Honolulu, HA) and collected into
DMEM containing endothelial cell growth supplement, 2mM L-glutamine, 10% fetal
bovine serum, and 5mM Hepes buffer. Samples were kept at RT prior to plating.
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Creation of 3D Fibrin and 3D Collagen I SVF Laden Cultures
Freshly isolated SVF was mixed in 10mg/mL bovine fibrinogen (Sigma Aldrich,
St. Louis, MO) dissolved in 50% normal saline and 50% rat complete media (1:1 vol:vol)
at 8x105 cells per 500µL. 2U of bovine thrombin (Sigma Aldrich, St. Louis, MO) was
added per mg fibrinogen to the solution. Collagen I gels were created at 4°C using purified
rat tail collagen I (Millipore, Temecula, CA) diluted to 3mg/mL in 4X DMEM base media
and Millipore water. Activation of polymerization was achieved by adding 7µL 4N NaOH
to reach a pH of 7.5 at RT. Aliquots of 500µL were plated in 48 well polystyrene tissue
culture treated plates (Corning, Corning, NY) and allowed to polymerize to a gel for 30
min at 37°C in a tissue culture incubator. 500µL of rat complete media was added and
replaced every other day on top of the polymerized gels for a culture length of 7 days.
Inhibitors in Culture
Inhibitors were added at each culture change to the media to reach the final
concentrations as follows: DAPT (g secretase inhibitor: 25µM) (Abcam, Cambridge, UK)
ZM306416 (VEGFR1 inhibitor: 25µM) (Selleckchem, Houston, TX), Imatinib mesylate
(PDGFR-b inhibitor: 1µM) (Sigma Aldrich, St. Louis, MO), LM609 (anti integrin aVb3
monoclonal antibody: 10µg/mL) (Millipore, Temecula, CA), and human recombinant Flk1
(soluble VEGFR2: 500ng/mL) (Abcam, San Diego, CA).
Imaging network formation and cell populations in 3D cultures
SVF in 3D fibrin or 3D collagen I at 7 days were fixed with 4% paraformaldehyde
for 15 min at RT, permeabilized with 0.1% Triton X 100 for 15 min at RT and stained with
griffonia simplicifolia 1 lectin conjugated to FITC (1:500) (Vector Biotechnologies,
Burlingame, CA) and a-smooth muscle actin mouse monoclonal primary antibody (1:500)

56

(Santa Cruz Biotechnology, Dallas, TX) overnight at 4°C to visualize endothelial and
smooth muscle cells respectively. Additionally, some samples were also stained overnight
at 4°C with rabbit monoclonal primary antibodies against nerve-glial antigen 2 (1:500), Ncadherin (1:500), or PDGF-Rb (1:500) (Santa Cruz Biotechnology, Dallas, TX) with
subsequent goat anti rabbit Alexafluor 594 secondary antibody (1:1000) (Thermofisher,
Rockford, IL) for 2 hours at RT to demonstrate pericyte cellular migration and association
with GS1 positive endothelial cell networks. 3D rendered images were captured using an
Olympus confocal microscope capturing Z-stacks at every 3µm tissue depth. OIF image
files were stitched into 3D composite images using AMIRA 6.0 software (FEI
Visualization Sciences Group). Composite, colored images were created using Image J
software (NIH).
Image Analysis
3D rendered images were analyzed using AMIRA 6.0 software. Microvessel tubes
were skeletonized in order to measure number of segments indicating branching
complexity, total vessel volume, and total vessel length. A segment is indicated as the
longest measurable endothelial tube before it branches to give off multiple extensions. All
image manipulation was conducted utilizing instructions from the AMIRA 6.0 user
manual.
Statistical Analysis
Graphs and statistics were run with GraphPad Prism v.7 Software (La Jolla, CA).
P values were calculated via one-way ANOVAs using Dunnet’s multiple comparison tests
with means and standard deviations plotted per group as compared to vehicle only (control
group). Paired t tests were calculated comparing collagen I and fibrin events including
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segment number, total vessel volume, total vessel length, and RNA expression level of
integrin subunit aV.
Gene Expression
3D embedded SVF was acquired at day 7 of culture and processed for mRNA
isolation. Briefly, gels were homogenized at 1:1 vol:vol of gel to trizol (ThermoFisher,
Waltham, MA) and subsequently processed using RNeasy kits (Qiagen, Hilden, Germany)
according to the provided manufacturer’s protocol. cDNA was produced from mRNA
using Agilent Affinity Script QPCR cDNA synthesis kit (Agilent, Santa Clara, CA) and
again processed via included protocol. cDNA was analyzed via RT-PCR using primers
designed against the rat integrin subunit aV from DNA sequences provided by PubMed
libraries. The forward primer: ‘CGA CCT TGC CGT TTT GGC TGC AGT T’ and the
reverse primer: ‘GGC CCA ACG TCT TCT TCG GTC TCA GG’ were added to obtain a
final concentration of 5µM along with Applied Biosystems SYBR Select Master Mix
(ThermoFisher) and run in the Qiagen Rotor Gene 6000 set to a 95°C hold cycle for 10
min, cycling repeats at 95°C, 59°C, and 72°C 40 times for 30 seconds and a melt and
cooldown cycle for 95°C for 10 min and 4°C for 1 hr. PCR product was quantified via 2%
agarose, TBE gel electrophoresis using a Bio-rad ChemiDoc imaging system (BioRad,
Hercules, CA).
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Results
Adipose-derived SVF forms robust microvascular networks in 3D fibrin
(10mg/mL) but not 3D collagen I (3mg/mL) within 7 days of culture (Figure 6).
Endothelial cells coalesce into highly branched networks as indicated by GS1-FITC+
staining. In addition, cells expressing alpha smooth muscle actin associate with endothelial
networks as demonstrated by aSMA-rhodamine+ cells adjacent to endothelial cells;
suggesting further maturation into multicellular microvessels more closely resembling
native arterioles (Figure 6A, Figure 7). These events do not take place in collagen I at
3mg/mL (Figure 6B). Rather, SVF cells embedded in collagen I are rounded and bunched
throughout 7 days of culture without significant migration, elongation, or branching with
no resemblance to endogenous microvascular architecture.
Additionally, due to the diverse population of cell types within SVF, it is noted that
cells resembling pericytes also migrate and associate to newly formed endothelial networks
in 3D fibrin cultures. This phenomenon is demonstrated through the expression of nerve
glial antigen 2, N-cadherin, and PDGFR-b positive cells associating with endothelial cells
(Figures 8, 9, 10). Interestingly, at 7 days, N-cadherin and PDGFR-b localization seem to
be highly peri-nuclear, suggesting production of high quantities of these proteins in the
rough endoplasmic reticulum or modification in the golgi before shuttling to the cell
surface.
Microvascular networks also remodel surrounding fibrin ECM and produce
basement membrane proteins including fibronectin and laminin 332 by day 7 (Figure 11
B, C).
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Figure 6: Rat SVF forms microvascular networks in Fibrin but not Collagen I. 4x105 Rat
SVF cells cultured in 250µL fibrin (10mg/mL) at 7 days. Endothelial cells are represented
by GS1-FITC+ (green) and alpha smooth muscle actin producing cells by aSMARhodamine+ (red) (A). Endothelial cells are rounded and do not resemble organization
into microvessel structures in collagen I (3mg/mL), in addition, there are very few alpha
smooth muscle actin producing cells (B). Scale bar =200µm.
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Figure 7: aSMA-Rhodamine+ perivascular cells associate with GS1-FITC+ endothelial
networks in 3D fibrin (10mg/mL) in vitro (A) Scale bar = 200µm. aSMA-Rhodamine+
perivascular cells only (B) Scale bar = 50µm. GS1-FITC+ endothelial networks only (C)
Scale bar = 50µm. Blue: DAPI+ nuclei. White arrows indicate endothelial cells without
surrounding cells.

Yellow arrows indicate areas of perivascular cells surrounding

endothelial cells.
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Figure 8: Rat SVF cultured in fibrin (10mg/mL) at 7 days demonstrating NG2+ cells
associating with endothelial networks. Phase contrast of microvessel morphology (A).
DAPI+ nuclear staining (B). Endothelial GS1-FITC+ cells (C). NG2-Alexa 594+ cells (D).
Composite merge of channels (E). Scale bar = 200 µm.
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Figure 9: Rat SVF cultured in fibrin (10mg/mL) at 7 days demonstrating N-cadherin+ cells
associating with endothelial networks. Phase contrast of microvessel morphology (A).
DAPI+ nuclear staining (B). Endothelial GS1-FITC+ cells (C). N-cadherin-Alexa 594+
cells (D). Composite merge of channels (E). Scale bar = 200 µm.
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Figure 10: Rat SVF cultured in fibrin (10mg/mL) at 7 days demonstrating PDGFR-b+ cells
associating with endothelial networks. Composite image of DAPI+ nuclear staining (blue).
Endothelial GS1-FITC+ cells (green). PDGFR-b+ cells (red).
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Figure 11: Rat SVF cultured in fibrin (10mg/mL) at 7 days demonstrating basement
membrane protein production around endothelial networks. GS1-FITC+ staining (green)
and DAPI+ nuclear staining (blue) (A). GS1-FITC+ staining (green), DAPI+ nuclear
staining (blue), and fibronectin-Alexa594+ staining (red) (B).

GS1-FITC+ staining

(green), DAPI+ nuclear staining (blue), and laminin332-Alexa594+ staining (red) (C).
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To understand if SVF microvascular network formation in 3D fibrin occurs through
similar angiogeneic mechanisms as seen in our previously published 2D SVF- Matrigelâ
assay160, inhibitors were added to 3D cultures at days 0, 2, 4 and 6. These inhibitors
included DAPT a g secretase inhibitor affecting the NOTCH pathway that decreases
differentiation of endothelial stalk cell phenotypes during angiogenesis;

ZM 306416 a

VEGFR-1 inhibitor also disrupting tip cell and stalk cell differentiation and tip cell
migration; Imatinib mesylate a competitive inhibitor of PDGFR-b disrupting perivascular
cell recruitment and stabilization of endothelial networks; LM 609 a monoclonal antibody
blocking ligand binding to integrin aVb3 potentially disrupting VEGF-induced
angiogenesis; and recombinant human VEGFR-2 (Flk1) a soluble VEGFR-2 that competes
for VEGF-A ligand extracellularly.
3D confocal images of SVF grown in 3D fibrin for 7 days were skeletonized using
AMIRA software to assess vessel complexity and density as measured by segment number,
total vessel volume, and total vessel length. Samples with inhibitor were normalized to
DMSO vehicle controls. In the presence of DAPT, samples demonstrated statistically
significant increases in segment number (p < 0.05), total vessel volume (p < 0.005), and
total vessel length as compared to DMSO (p <0.05) (Figures 12, 13). This may be due to
dysregulation of tip and stalk cell ratios.

Indeed, in a diabetic mouse model of

angiogenesis, reduced endothelial sprouting and migration were noted by Cao and
colleagues, however, in the presence of PDGF, VEGF, and DAPT, vessel density increased
150%172. We see similar phenomena in our in vitro assay with as much as 2-fold total
vessel volume increases and 1.5-fold segment number and total vessel length increases
(Figure 13). These increases in vessel segment number, volume, and length, however, do
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not indicate that these microvessels are fully functional. In order to assess functionality,
engineered microvasculature must be implanted in vivo, inosculate with host microvessels
to establish flow, and demonstrate retention overtime post pruning.
In the presence of ZM 306416, a VEGFR1 inhibitor, there are statistically
significant decreases in vessel segment number (p < 0.0005), vessel volume (p < 0.05), and
total vessel length (p < 0.0001) (Figure 12, 13). When treated with Imatinib mesylate,
there are also statistically significant decreases in segment number (p < 0.005) and total
vessel length (p < 0.0005) (Figure 12, 13). The integrin aVb3 inhibitor LM609 at 10µg/mL
also reduces SVF microvessel formation and complexity in 3D fibrin.

There is a

statistically significant decrease in segment number (p < 0.0005), total vessel volume (p <
0.05), and total vessel length (p < 0.0001) as compared to DMSO control. Finally, in the
presence of recombinant Flk1 at 500ng/mL, there are also significant decreases in segment
number (p < 0.005), total vessel volume (p < 0.05), and total vessel length (p < 0.0005)
(Figure 12, 13).
To assess if fibrin or collagen differentially alter expression of integrin aVb3 in SVF
derived microvessels, RNA was isolated from 3D cultures after 7 days. Unfortunately,
only the sequence of the aV subunit was known for rats through database searching, and as
such, primers were designed against that subunit. Interestingly, after 7 days, there was no
significant difference between the expression profile of aV as normalized to the
housekeeping gene GAPDH between fibrin and collagen I cultures (Figure 14).
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Figure 12: 3D rendered confocal zstacks of rSVF in 10mg/mL Fibrin, day 7.
Endothelial cells stained with GS1-FITC
(Green) with samples: DMSO vehicle
only (A, B), 25µM DAPT (C, D), 25µM
ZM 306416 (E, F), 1µM Imatinib
mesylate (G, H), 10µg/mL anti-𝛼V𝛽3 mAb
(I, J), and 500ng/mL soluble human
recombinant Flk1 (K, L). Inhibitors were
added to culture at days 0, 2, 4, and 6
during media changes. Images B, D, F,
H, J, L are skeletonized renderings of
vascular

structures

using

AMIRA

software to calculate segment number,
total volume, and total length of vessels
in vitro. Change in vessel color from blue
to green to yellow to orange represents
increasing diameter of tube structure in
skeletonized images.
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Figure 13: A. Number of vessel segments normalized to vehicle control with significant
increase in segment number in the presence of DAPT and significant decrease in segment
number in the presence of ZM 306416, Imatinib mesylate, anti-𝛼V𝛽3 mAb, and soluble
Flk1. B. Total volume of vessel structures normalized to vehicle control with significant
increase in total vessel volume in the presence of DAPT and significant decrease in total
vessel volume in the presence of ZM 306416, anti-𝛼V𝛽3 mAb, and soluble Flk1. C. Total
vessel length normalized to vehicle control with significant increase in total vessel length
in the presence of DAPT and significant decrease in total vessel length in the presence of
ZM 306416, Imatinib mesylate, anti-𝛼V𝛽3 mAb, and soluble Flk1. p < 0.05 (*), p < 0.005
(**), p < 0.0005 (***), p < 0.0001 (****).
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Figure 14: Gene expression of integrin 𝛼V subunit normalized to GAPDH
expression. RNA was isolated from rSVF cells (4x105cells/250𝜇L gel) embedded in either
10mg/mL fibrin or 3mg/mL collagen I, cultured over 7 days. RNA was converted to cDNA
and amplification with primers to the housekeeping gene GAPDH as well as the integrin

𝛼V subunit was performed via PCR. There is no significant difference in expression of
integrin 𝛼V subunit normalized to GAPDH between SVF grown in fibrin and collagen I.
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Discussion
To create microvasculature from adipose-derived SVF, clinically available and
translatable reagents have been a focus of studies to provide a 3D structure and support
angiogenesis in vitro. If achieved, this would allow for the construction of implantable,
discreet, pre-vascularized tissue units for in vivo purposes. Nicosia and colleagues were
able to create an in vitro aortic ring model to stimulate and study angiogenesis in 3D,
however, this model does not translate to the production of prevascularized 3D tissue for
clinical applications144. 3D fibrin at 10mg/mL stimulates rapid formation of microvessels
derived from embedded, freshly isolated SVF cell populations, while 3mg/mL collagen I
does not over a period of 7 days. As such, it was hypothesized that preferential integrin
activation by fibrin stimulates angiogenesis in our 3D culture system.
Many different types of integrins are ubiquitously expressed in adult tissues,
however, fibrin-activated integrin 𝛼V𝛽3 is most abundantly expressed on endothelial cells
participating in angiogenesis during tissue remodeling, growth, and pathogenesis, but not
expressed in normal quiescent endothelial cells173. More specifically, the 𝛽3 subunit
expression decreases as early as the first weeks of life during remodeling of cardiac blood
vessels as seen in mice174. However, in knockout studies, mice lacking 𝛽3 not only have
increased hemorrhagic events in utero, but also, capillaries in the heart fail to mature and
create lumens via vacuolar formation, presenting similarly to immature non-functional
endothelium.

Indeed, a molecular complex and activation is needed between both

VEGFR2 and integrin 𝛼V𝛽3 during angiogenesis169,175-177. Integrin 𝛽3 subunit expression
is necessary to stimulate endothelial morphogenesis, and also, it is required for the
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recruitment of bone marrow derived cells to sites of angiogeneic remodeling via signaling
release events from the bone marrow space178.
As stated prior, integrin 𝛼V𝛽3 and others are activated by extracellular matrix
proteins containing the RGD motif such as vitronectin, fibrinogen, and fibrin. The receptor
itself is highly internalized through known clathrin-dependent endocytosis. Some have
studied the production of internalizing-RGD proteins (iRGD) or RGD-targeted
nanoparticles to image highly angiogenic tumor vascular structure

179,180

. In addition,

inhibitors of integrin 𝛼V𝛽3 are produced endogenously to mitigate hyper-angiogenesis as
seen in solid tumor growth. Some of these inhibitors are soluble protein fragments that
mimic and compete with insoluble endogenous ECM for integrin binding. For example,
angiostatin is a plasmin fragment that binds to 𝛼V𝛽3181, canstatin is a type IV collagen
fragment binding to 𝛼V𝛽3 and 𝛼V𝛽5182, endostatin is a collagen XVIII fragment that binds
to 𝛼V𝛽3, 𝛼V𝛽5, and 𝛼5𝛽1183, and tumstatin is a type IV collagen fragment that binds to 𝛼V𝛽3
and 𝛼5𝛽1184.
Synthetic inhibitors have also been tested as means to interrupt integrin 𝛼V𝛽3dependent angiogenesis in solid tumors. Of note is Cilengitide, an RGD peptide, which
has undergone Phase III clinical testing for patients with glioblastoma multiforme,
demonstrating durable remissions and increased survival for some patients185. In addition,
the anti- 𝛼V𝛽3 antibody LM609 demonstrating inhibition of angiogenesis in a chick embryo
model was also humanized and is being developed by Astra-Zeneca as etarazizumab
(Abegrin) with early phase I studies demonstrating tolerability in patients with solid tumors
as well186.
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In our assay, SVF forms robust microvascular networks in 3D fibrin in an integrin
𝛼V𝛽3-dependent manner. In the presence of LM609, there was significant decreases in
vessel segment number, total vessel volume, and total vessel length. In addition, SVFformed microvessels in fibrin require known angiogenic signaling pathways to function for
network formation. In the presence of VEGFR1 inhibitor, PDGFR-𝛽 inhibitor, as well as
soluble VEGFR-2, there is decreased microvessel segment numbers, total vessel volumes,
and total vessel lengths as compared to controls. Additionally, microvessels formed within
3D fibrin in vitro not only undergo endothelial tubulogenesis, but also recruit perivascular
support cells in the form of NG2+/PDGFR-𝛽+ pericytes and alpha smooth muscle actin
producing cells, suggesting continual maturation mimicking endogenous functional
microvasculature.
While not all mechanisms are fully understood, it is possible that in addition to
integrin 𝛼V𝛽3 activation and VEGFR2 signaling, biomechanical factors such as tensile
strength, fibril alignment and orientation, and deformability of 10mg/mL fibrin gels allows
for increased cellular migration and proliferation as compared to 3mg/mL collagen type I
constructs. Additional studies are needed to elucidate specific mechanisms involved in
SVF vasculogenesis and angiogenesis in 3D fibrin, in addition to known integrin signaling
pathways.
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CHAPTER III
BIOPRINTING SVF-DERIVED MICROVASCULATURE AND ELECTROSPINNING
SVF-DERIVED MACROVASCULATURE

The Formation of SVF-Laden Spheroids Utilizing a 3D Bioprinter and
Superhydrophobic Surfaces

Introduction
Currently, clinical therapies utilizing SVF and other stem cell sources for
transplantation often administer cells through means of direct injection, where cells are resuspended into a sterile solution and delivered via syringe to sites of interest20-22,104,120,187190

. Unfortunately, with these procedures, many cells do not retain at the site of injection

and rather migrate, enter circulation, or undergo apoptosis due to poor integration with
diseased tissue191,192. To mitigate the problems seen with cell suspensions, many have
studied in vitro cell assembly into aggregates, whereby cells are either encapsulated in
biomaterials such as extracellular matrix or self-aggregate into cell clusters via specific
culture methods193-196. As an example, SVF as a clinically utilized cell source has been
encapsulated into hydrogels which include 3D collagen I and alginate for in vivo
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applications67,81,197-202.

Most encapsulation methods are simple 3D culture systems

creating known geometries afforded by commercially available well-based polystyrene
plates. However, of late, systems producing a spheroid format have shed new light on
encapsulation of cells, reducing necrotic zones in vitro, and allowing discrete tissue units
to be delivered in vivo.
Cell only spheroids, surface cell sodded spheroids, and cells encapsulated within
hydrogel spheroids are the primary methods for creation of new format tissue units in a
spheroid geometry. Specifically, cell only spheroids are created through self-aggregation
in which cells communicate with one another forming tight adhesion junctions during the
process of hanging within a droplet of media. However, this production process takes
several days and is highly dependent upon rates of claudin and occludin association
between cells which can vary drastically between cell types203,204.

Surface sodding

premade spheroids is also highly dependent upon cells’ adhesive properties, which can
limit biomaterial used, and in some cases, limit cellular integration, migration, and
proliferation into the entire spheroid, possibly due to cells’ inability to digest and remodel
the biomaterial during migration. The final type of cell spheroid production is through
encapsulation of cells within a biomaterial that can undergo phase change from liquid into
gel form, embedding cells throughout the entire spheroid unit. Cell embedding has the
advantages of equal distribution of cells within the entire spheroid, the ability to dose the
amount of cells per spheroid creating advantageous ECM to cell ratios, and the ability to
be produced in less than one day201,205-209.
Previously, there have been some limitations with ECM spheroid productions
specifically utilizing collagen I or fibrin. These ECM proteins while adhesive and allowing
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for signal transduction, migration, proliferation, differentiation and remodeling by cells, do
not retain shape unless crosslinked within a mold. Thus, it was imperative to develop new
techniques allowing natural polymerization of cell laden hydrogels into replicable, precise
tissue spheroids.
Extrusion printing is a customizable and well-established method of manufacturing
specific 3D architectures, commonly utilizing non-biologics such as plastics and glass. As
a subset method of 3D printing, extrusion bioprinting affords the use of biologically
applicable hydrogels without the need of curative agents or other potential toxins as seen
in manufacturing methods such as sterolithography. Many have utilized 3D axis, direct
write CAD/CAM based 3D printers to extrude biomaterials with or without cells
present210,211. As such, we found it necessary to approach similar systems in order to create
SVF laden collagen I and fibrin spheroids for potential in vivo applications.
In order to produce replicable, exact shapes, simple extrusion of non-polymerized
ECM such as collagen I would have to utilize plastic molds or shape holders due to the
biomaterial not retaining certain architectures even post polymerization; introducing issues
such as manual handling and removal which may damage or alter scaffolds and provide
unnecessary variability.

Such methods would limit clinical translatability of tissue

engineered products. In addition, in vivo applications may require certain irregular shapes
or patient specific cell doses that would force additional manipulation of 3D bioprinted,
molded scaffolds. Instead, herein we describe a technique to automate and 3D print
collagen I and fibrin containing SVF in spheroid format utilizing superhydrophobic
surfaces, hydrophilic spotting, and extrusion bioprinting.
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Collagen and fibrin cell

containing spheroids may address aforementioned issues with fluid-suspended cellular
injections and their limited retention at pathologic sites.
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Materials and Methods
Fabrication of a Superhydrophobic Surface
A superhydrophobic surface was produced on polystyrene 48-multiwell plates
(Corning, Corning, NY) and/or 35mm Petri dishes using a two-step aerosol application of
NeverWetTM (Rust Oleum, Vernon Hills, IL). The application of a binder to the surface as
a base coat was sprayed onto non-treated plates and allowed to dry at RT for 1h. Secondly,
a top sheet composed of polydimethylsiloxane modified with hexamethyldisilazane was
added to form a superhydrophobic layer. The entire superhydrophobic layer was measured
as 0.007mm. The plates were allowed to air dry for at least 1 more hr before the addition
of hydrophilic spots. NeverWetTM has a reported contact angle of 165° which meets the
criteria of hydrophobicity (contact angles > 150°). The contact angle of both water and
unpolymerized collagen I (3mg/mL) was measured using side view photography and angle
measurement tools in ImageJ (NIH, Bethesda, MD).
Creation of Hydrophilic Spots
Hydrophilic spots onto the superhydrophobic surface were created using a direct
write 3D biporinter (Bio-Asssembly Tool (BAT) 3D Printer; nScrypt, Inc., Orlando, FL)
to extrude Pluronic F-127 (Sigma Aldrich, St. Louis, MO). For each hydrophilic spot, the
BAT extruded a target volume of 2µL of 3.8% (wt/wt) Pluronic F-127 in 1X phosphatebuffered saline (PBS). Using time-pressure extrusion, this required 2.5psi with an exposure
time of 100ms through a 25G needle in order to create the extrusion force necessary to
meet the target volume. The spots were then allowed to air dry for 30min before use.
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Animals and Ethics Statement
All animal procedures were conducted in compliance with University of Louisville
School of Medicine IACUC-approved protocols and NIH guidelines. Isoflurane gas was
administered for anesthesia.
SVF Isolation from Sprague Dawley Rats
Rat epididymal fat pads were excised from 6 to 8-month-old Sprague Dawley rats
at weights greater than 250g under sterile surgical procedure and isoflurane anesthesia. All
procedures were reviewed and approved under the University of Louisville’s Institutional
Animal Care and Use Committee. Excised fat pads were placed in PBS containing 0.1%
bovine serum albumin (Sigma Aldrich, St. Louis MO) and kept at 4°C for 15 min prior to
digestion. Samples were washed with BSA-PBS and minced for 2 min until particulates
could pass through a 50mL aspirating pipette. 2mg of Type I Collagenase (Worthington
Biochemical Corporation, Lakewood NJ) was added per mL of fat, aliquoted at 20mL total
volume in 50mL conical centrifuge tubes, and rotated in an Envirogenie Incubator
(Scientific Industries, Bohemia, NY) at 35 rpm and 37°C for 35 min. Samples were
pelleted via centrifugation at 350xg for 4 min at RT. Buoyant adipocytes were aspirated
and discarded, and dense cellular pellets were suspended and washed one time in BSAPBS. Samples were re-centrifuged for 4 min at 350xg. The SVF pellet was filtered through
a 250µm mesh filter (Tissue Genesis Incorporated, Honolulu HA) and collected into
DMEM containing endothelial cell growth supplement, 2mM L-glutamine, 10% fetal
bovine serum, and 5mM Hepes buffer. Samples were kept at RT prior to bioprinting.

79

SVF Cell-laden Collagen, Fibrin Spheroid Fabrication
Freshly isolated SVF was suspended in unpolymerized rat tail collagen I (Millipore,
Temecula, CA) mixed with 1X Dulbecco’s modified Eagle’s medium (DMEM) (Sigma
Aldrich, St. Louis, MO) titered to a final pH of 7.4 utilizing 4N NaOH to create a 3mg/mL
collagen I solution containing 1.6 x 106 SVF cells/mL. The mixture was kept at 4°C prior
to printing. The SVF-collagen I solution was transferred to a 3mL printing syringe (EFD,
Nordson, Westlake, OH) and loaded into a time/pressure-based 3D Bioprinter (Biological
Architecture Tool (BAT) nScrypt, Inc., Orlando, FL) where the mixture was continually
cooled to 4°C using a refrigerant copper coil system encompassing printing syringes. The
initial printing conditions were based on our previously published data for continuous
cylinder printing81,211-213. SVF in bovine fibrinogen (10mg/mL) (Sigma Aldrich, St. Louis,
MO) dissolved in 50% normal saline and 50% rat complete media and was printed using
similar extrusion parameters as collagen I. Post printing, spheroids were incubated in a
tissue culture incubator (37°C, 5% CO2) for 10 min to allow hydrogel polymerization.
Spheroid Culture Methods
Spheroids were incubated in rat complete media composed of DMEM, 10% FBS,
5mM HEPES buffer, 2mM L-glutamine, endothelial growth supplement containing
heparin, penicillin (45U/mL) and streptomycin (45µg/mL) in a spinner flask (125-mL
MagnaFlex, Microcarrier Spinner Flask; Wheaton Industries, Millville, NJ). The spinner
flask was placed onto a magnetic stirrer platform (MCS 104-L Biological Stirrer, Techne,
Inc., Burlington, NJ) set to 40rpm over the entire culture period (14 days). For fibrin
spheroids and spheroid contraction studies, individual spheroids were plated in separate
wells of a 96-well ultra-low attachment plate (Corning, Corning, NY).
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Spheroid Size Measurements
Images of spheroids were obtained through light microscopy using a 4X objective
attached to an Olympus CKX41 light microscope (Olympus, Tokyo, Japan). Diameters
were measured using ImageJ Software.
Live/dead Assay
SVF embedded in 3D collagen I spheroids were assessed for viability using the
Live/Dead Viability/Toxicity Kit (Life Technologies, Inc., Carlsbad, CA).

Briefly,

spheroids were washed with PBS, incubated in 10µM calcein AM (live) and 10µM
ethidium homodimer-1 (dead) at RT for 45 min. Samples were washed again and imaged
using an Olympus IX71 epifluorescent microscope (Olympus, Tokyo, Japan). In order to
quantify live and dead cells, standard curves were created using unembedded SVF cells at
known amounts and counting live dead ratios with a NucleoCounter (ChemoMetec,
Allerod, Denmark) for non-fluorescence, and a Cytation 5 Imaging Multi-Mode Reader
(BioTek, Winooski, VT) for fluorescence. Utilizing the standard curve, cell viability in 3D
spheroids was measured on days 0, 2, 6, 9, and 13. Distribution of cells within the spheroid
was assessed via Hoechst 33258 bis-benzimide nuclear staining (Anaspec, CA) following
15min permeabilization with 0.1% Triton X-100 (Sigam Aldrich, St. Louis, MO).
Confocal Microscopy
For in vitro assessment of embedded SVF differentiation into microvessel
structures, a MPE FluoView1000 confocal microscope was used along with a 10X water
immersion objective to capture the entire spheroid in 1 frame (Olympus, Tokyo, Japan).
Confocal image z-stacks were reconstructed into a 3D image using AMIRA 3D

81

visualization software (Thermo, Waltham, MA). Briefly, Spheroids at 11 days were fixed
with 4% paraformaldehyde for 10min at RT, then permeabilized with 0.1% Triton X-100
(Sigma Aldrich, St. Louis, MO) for 15 min at RT. Following permeabilzation, spheroids
were stained with Griffonia Simplicifolia-1 Isolectin 4 conjugated to FITC (GS1; Vector
Laboratories, Burlingame, CA) at a dilution of 1:500. Additionally, mouse monoclonal asmooth muscle actin primary antibody was added at 1:250 (Santa Cruz Biotechnology,
Dallas, TX). Spheroids were incubated overnight at 4°C. The following day, spheroids
were washed 3X in PBS, and incubated with RedDot nuclear stain (Biotium, Fremont, CA)
and goat anti-mouse IgG Alexa Fluor 594 secondary antibody (Thermo Fisher, Waltham,
MA) at 1:200 and 1:1000 dilutions respectively for 2hr at RT. Endothelial cells stained
green and were positive with GS1-FITC, and aSMA containing cells stained red. All cell
nuclei stained with RedDot were artificially colored blue.
Statistical Analysis
One-way ANOVA with Dunnett’s multiple comparison was used to determine
statistical significance between mean spheroid diameters calculated at day 2 and all other
acquired time points. Graphs were created using GraphPad Prism v.7 software (GraphPad
Software, Inc., La Jolla, CA).
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Results
3D Biporinting Parameters
The BAT was capable of both time and pressure regulated extrusion of all
biomaterials including Pluronicâ F-127, collagen I, and fibrinogen at various
concentrations and viscosities relying on multiple pen extrusion tips. Contact angles of
spheroids and superhydrophobic surfaces were recorded at 155° for water, and 156° for
unpolymerized collagen I containing SVF (data not shown). Extrusion parameters were
selected in order to produce spheroids of consistent size and shape at a rate of 10.3
spheroids/min.

Specific parameters adjusted included syringe volume (3cc), syringe

pressure (5 psi), pressure duration (100ms), and needle gauge (18G blunt) (Table 1). While
multiple parameters were tested, higher pressures as well as larger needle gauges afforded
more consistent results and were thusly selected. In order to maintain spheroid volumes at
roughly 25µL, pressure duration was kept low (100ms). Syringe volumes were selected to
accommodate batch volumes of > 100 spheroids per print. Collagen concentrations as well
as fibrinogen concentrations were selected based off of previously published data
demonstrating robust angiogenesis by microvessel fragments or SVF cells within these 3D
culture systems.
Spheroid Bioprinting
In order to produce discreet spheroids of uniform size, it was necessary to extrude
collagen I prior to its polymerization while still in liquid format. However, if extruded on
normal untreated polystyrene, cohesive effects would not allow the maintenance of
spheroid architectures and would flatten and spread prior to polymerization. Thus, it was
imperative to design superhydrophobic surfaces to allow consistent spheroid production.
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To immobilize spheroids when bioprinted onto superhydrophobic surfaces, hydrophilic
spots were printed using Pluronicâ F-127 (Figure 15). Pluronic was chosen due to its
amphiphilic properties as well as phase change properties that would allow precise flat
cylinders to immobilize collagen spheroids, and also, post collagen polymerization, for
spheroids to be easily released by simple temperature decrease to 10°C. Spheroid position
was retained post printing during motorized stage movements (X-Y axes) as well as during
transfer of plates to a tissue culture incubator. Spheroids were easily removed upon
pluronic phase change and maintained size and shape over these processes.

Entire

production time was roughly 30-35min before spheroid usage; equating to roughly 5 min
per 48 spheroids produced, 20 min instrument preparation time, and 10 min of
polymerization time post print.
Spheroid Morphology and Cell Viability
Using volumes of 2mL, approximately 100-150 spheroids were produced
containing SVF at 4x105 cells/250µL, or roughly 4x104 cells/spheroid. Spheroids had a
mean diameter of 3.54mm immediately post print with a standard deviation of 0.195mm.
Cell viability of SVF embedded in spheroids in spinner culture, was assessed at 2 days and
6 days post print (Figure 16). Cells were distributed evenly throughout the entire hydrogel
(Figure 16a) immediately post print and throughout the culture period. In addition, the
majority of the cells remained viable as measured at 2 and 6 days in culture with some cells
undergoing apoptosis as seen by positive ethidium homodimer staining. Polymerization
times were sufficient to retain heterogeneity in cell distribution without notice of dense cell
settling in specific locations of spheroids. Interestingly, at 6 days post culture, retained
microvessels within collagen I demonstrated angiogenic events such as sprouting,
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morphological characteristics seen by calcein AM live stains (Figure 16f). Angiogenic
events were noticeable at earlier time points in 10mg/mL fibrin spheroids at day 4 by phase
contrast microscopy (Figure 17).
SVF viability was quantified at days 0, 2, 6, 9, and 13 (Figure 18). Immediately
post print, 68.24% ± 3.59% of cells were viable, 5.96% lower than non-printed, pipetted
controls, and 27.8% lower than initial media-suspended cell counts via NucleoCounter,
suggesting that collagen I and its pH change may alter cell viability post encapsulation,
however, pressures afforded due to extrusion printing do not significantly affect cell
viability during spheroid production (Figure 19).
Over 14 days in culture, collagen and fibrin spheroids undergo contraction with a
concomitant decrease in diameter (Figure 18, 20). However, contraction rates are not
uniform during the 14-day culture period. Specifically, from days 2 to 3, collagen
spheroids decreased on average 0.0083 ± 0.0875mm/day all the way to 0.3675 ±
0.1359mm/day from days 6 to 7. However, contraction rates reduced from days 9 to 13
(0.042 ± 0.0463mm) suggesting that cells are possibly remodeling or digesting the matrix
as they migrate and proliferate at the highest rates around 7 days in spinner culture.
Average spheroid diameters were significantly different between days 2 and each
subsequent day in spinner culture (p < 0.0001) (Figure 20).
As spheroids contract, light microscopy is not sufficient to analyze embedded
cellular morphology due to the extreme density of cells and collagen I, not affording
sufficient light passage. As such, we analyzed cellular morphology looking specifically
for microvessel formation and in vitro maturation via confocal microscopy of spheroids at
day 14 to render a z-stack 3D image.

To analyze neovascularization morphology,
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endothelial cells were stained with GS1-FITC, and a-smooth muscle actin positive
(perivascular support cells/mural cells) were stained with an Alexa Fluor 594 conjugated
primary antibody against cytosolic aSMA (Figure 21). Endothelial cells form networks
mimicking endogenous microvasculature with areas of aSMA positive cells surrounding
endothelial tubes. However, in 3mg/mL collagen I spheroids, microvessel density is less
than that in 10mg/mL fibrin spheroids. These data are similar to our previously published
data with SVF in 3D collagen I and 3D fibrin in vitro.
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Printing Parameter

Selected Value

Range Evaluated

Syringe pressure

5 psi

3-6 psi

Pressure duration

100 ms

100-300 ms

BAT cartridge size

3 cc

3 cc

Needle gauge

18 G, blunt

18-25 G, blunt

Collagen I concentration

3 mg/mL

3 mg/mL

a
b
c

d
e

Table 1: Conditions to Print 3D Spheroids Using the Bioassembly Tool Bioprinter.
a

Pressure effects were evaluated during 100ms of duration. bTime of pressure extrusion

was evaluated at a constant 5 psi. cThe nScrypt Bioassembly Tool utilizes EFD cartridges
in a precision fluid dispensing system (Nordson Corporation, Westlake, OH). dNordson
EFD extrusion tops. eRat tail-derived collagen I.
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Figure 15:

Photographs of SVF-laden 3mg/mL collagen spheroids immediately post

bioprinting (a-c).

Diagram demonstrating biphilic surface properties allowing for

spheroid formation of aqueous substances using hydrophobic coatings and hydrophilic
immobilization spots (Pluronicâ F-127) (d).
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Figure 16: SVF encapsulated in 3mg/mL collagen I spheroids, Live/Dead Analysis. Phase
contrast microscopy of SVF laden collagen I spheroids at day 2 (a) and day 6 (e). Calcein
AM live stain at day 2 (b) and day 6 (f). Ethidium homodimer-1 dead cell stain at day 2
(c) and day 6 (g). Hoeschst 33258 bis-benzimide nuclear stain at day 2 (d) and day 6 (h).
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Figure 17: SVF-laden 10mg/mL fibrin spheroids at day 1 (a, c) and day 4 (b, d) in culture.
Microvascular network phenotypes are present in day 4 culture spheroids.

Similar

morphologic events do not occur in collagen I until day 6 with SVF-derived microvessel
fragments present.
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Figure 18: SVF viability in 3mg/mL collagen I spheroids at days 0, 2, 6, 9, and 13. There
is no significant change in viability over the 2-week culture period of embedded cells.
There is a trend towards increased viability over time.

91

Figure 19: 3mg/mL Collagen I spheroids containing SVF undergoing contraction on days
2 (a), 6 (b), 9 (c), and 13 (d) in spinner culture. There is significant remodeling of collagen
by SVF cells which causes spheroids to contract, increase in density, and decrease in
diameter.
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Figure 20:

3mg/mL collagen I spheroids containing SVF decrease in diameter

significantly between days 2 and all other subsequent days in spinner culture. (n = 12, * p
< 0.05, *** p < 0.001, **** p< 0.0001).
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Figure 21:

SVF containing

microvessel

fragments

undergoes angiogenesis when
embedded and cultured over
14 days in bioprinted 3mg/mL
collagen I spheroids. Phase
contract microscopy following
11 days in culture (A) scale
bar = 100µm. Phase contrast
image

demonstrating

increased

density

contraction

of

the

and
same

spheroid at 12 days in culture
(B) scale bar = 100µm. Phase
contrast image demonstrating
angiogenic sprouting as indicated by arrows in 8 days culture (C) and 11 days culture (D)
scale bar = 50µm. Confocal z-stack image demonstrating microvessel structures within
collagen I spheroids are made up of endothelial cells (GS1-FITC+, green) and aSMA
containing cells (aSMA-Alexa Fluor 594+, red) and have branching morphology (arrows)
after 14 days in culture (E, F, G) scale bar = 100µm (E), scale bar = 50µm (F, G).
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Discussion
Many clinical trials are currently studying the use of stem and other regenerative
cells for delivery to pathological tissues with the hopes of therapeutic tissue remodeling
through exogenous cell proliferation and/or release of paracrine factors stimulating
endogenous cell proliferation and/or function. While therapies have seen functional
benefits such as increases in ejection fraction for example, many have demonstrated limited
cell retention at sites of implantation rendering unremarkable therapeutic effect20-22. As
such, additional methods for discrete in vitro tissue formation have been studied, whereby
cells are cultured to promote self-aggregation, or hydrogels are utilized to create 3D
systems that can provide a stimulating microenvironment for embedded cells in order to
mature into tissue units88,214. Most 3D systems utilize a mixture of cells with a scaffold or
substrate that provides sites for cell adhesion and migration, as well as threedimensionality, more closely mimicking endogenous tissue histological layouts. Our lab
and others have studied extensively the creation of tissue engineered microvessels utilizing
adipose-derived SVF cell populations embedded in 3D collagen I and fibrin67,95,215.
To create dosable, discrete, viable, tissue units with limited handling and
manipulation, however, it was imperative to develop a new model of production.
Previously we were able to bioprint SVF in materials such as alginate into a spheroid
format utilizing direct-write 3D bioprinting and automation through CAD/CAM
systems209,212. Unfortunately, while SVF cells remained viable in alginate, they did not
undergo typical morphogenic alteration forming microvessels through vasculogenesis and
angiogenesis as seen in our other culture systems utilizing collagen I and fibrin.
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Most in vitro tissue engineering utilizing collagen I and similar ECMs require
crosslinking of liquid collagen to form gel collagen which occurs after pH change in a mold
such as a tissue culture plate. This however introduces problems when trying to remove
3D constructs from plates for in vivo implantations.

Handling inevitably produces

variations and damage to 3D ECM during the removal process due to high adherence
between ECM and polystyrene. As such, we found it necessary to reassess bioprinting
spheroids onto superhydrophobic surfaces which would mitigate adhesion problems, as
well as allow for rapid production of spheroid architectures through automated methods.
Initial printing on non-treated, polystyrene tissue culture plates of both collagen I
and fibrin resulted in flattening of SVF/hydrogel solutions prior to their polymerization,
creating non-implantable 3D tissue sheets. Additionally, after superhydrophobic coating
and during subsequent extrusion based bioprinting, liquid droplets of collagen I containing
SVF would not release from pen tips onto the superhydrophobic surface. To overcome this
lack of adherence, a disk of Pluronicâ F-127, a triblock co-polymer with amphiphilic
moieties was printed onto the superhydrophobic surface which allowed for collagen I liquid
droplet removal post extrusion from the pen tip, as well as spheroid architecture to form
due to pluronic disk diameters of 500µm or less.
Extrusion based bioprinting using our afformentioned parameters allowed tailoring
of spheroid sizes and volumes based on applied syringe pressures. Spheroids could be
produced ranging in size from 1mm to 3.5mm in order to prevent core necrosis due to lack
of nutrient diffusion. SVF cells embedded in fibrin as well as SVF cells + SVF-derived
microvessel fragements embedded in collagen I all underwent angiogenesis over the
culture period of 14 days without noticeable necrotic cores or increased apoptosis. Fibrin
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spheroids would demonstrate microvessel morphologies faster in culture than collagen I
spheroids. These events can be described as phenotypic orientation of endothelial cells as
well as perivascular cells into branching structures.

However, in order to assess

microvessel function, further studies are needed after spheroid implantation in vivo to
analyze if microvessel-spheroid-tissue units innosculate with host vasculature and provide
blood flow to areas of interest.
Automation through direct-write computer-assisted design and manufacture allows
the opportunity to create discrete spheroids containing cells in a very precise and controlled
manner with high throughput, and tailor ability relevant to a clinical point-of-care setting.
Creating spheroid architectures allows cells to grow in 3D culture without adhering to
plates and receive nutrients without undergoing apoptosis. In addition, known spheroids
can be dosed with specific amounts of cells and spheroids themselves can be delivered to
pathological tissues via large gauge syringes in known quantities. With regards to our
studies with SVF, cells embedded within collagen I spheroids or fibrin spheroids still
undergo angiogenesis and may be a way to deliver discrete microvascularized tissue units
to patients in the future.
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The Creation of Blood Vessel Mimics Utilizing Electrospinning and Cell Sodding
Technologies.

Introduction
Atherosclerosis is a primary cause of acute myocardial infarction in which coronary
artery lumenal occlusion and cessation of blood flow occurs due to build-up of plaques in
vessel walls. Commonly, patients undergo either percutaneous angioplasty or surgical
bypass to reestablish blood flow to injured myocardium. Surgical bypass grafts are usually
harvested from the saphenous vein or from the internal mammary artery. However, in
patients with comorbidities or patients undergoing multiple bypasses, available
endogenous conduit vessels may be limited. As such, many have researched the production
of artificial blood vessel mimics (BVMs) through multiple technologies as potential
options for surgical bypass vessels79,216-220.
Already of clinical utilization are materials such as dacron or expanded
polytetrafluoroethylene (ePTFE), also known as Gore-Texâ for large vessel bypasses.
These materials are successful for large vessels but unsuccessful for small diameter vessels
(< 6 mm) due to their high rate of thrombogenicity at small diameters and limited
endothelialization past a distance of 2 cm distally from native vessel anastomosis221.
Reported patency rates are only 40% post six months surgery and 25% post 3 years222.
Additionally, these materials are non-degradable and allow for limited cellular ingrowth.
As such, there is a need for new techniques to tissue engineer biodegradable vessels that
can provide mechanical stability, tissue morphology including ECM mimicry, and
appropriate porosity for cellular integration.
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Electrospinning is a process in which fibers ranging in sizes from 50 to 500 nm are
produced via Taylor cone jetting across a high voltage potential223. Specifically, a voltage
is applied to a liquefied, viscoelastic, polymer solution changing its charge, providing
movement to a grounded object such as a collection mandrel when the charge force
overcomes the solution’s surface tension. The liquefied polymer, as it moves through the
air in a whipping fashion, evaporates the solvent and fibers are left for deposition onto a
collection surface producing a randomly-oriented fibrous mat or tube. Fiber morphology
can be changed by altering electrospinning parameters such as solution viscosity, electrical
conductivity, polymer molecular weight, flow rate of solution, spinning distance, applied
voltage, and humidity and temperature224. Altering parameters allows high variation in
electrospun products for the production of micro-scale textures and pores resembling
endogenous ECM, allowing cellular infiltration either in vivo or in vitro225.
Common polymers used in electrospinning include polycaprolactone (PCL), poly
(L-lactide-co-e-caprolactone) (PLCL), poly-lactic acid (PLA), polyurethane (PU), Llactide-co-trimethylene carb, and polypropylene21,226-233. Many publications describe PCL
based-blood vessels that demonstrate good mechanical properties such as longitudinal
stress and strain to rupture requiring high pressures, as well as strong suture strength and
burst pressure226. In addition, electropsun PCL can be tailored to a wide variety of fiber
thickness which may play an additional role in cellular migration and adherence. From a
clinically translatable standpoint, PCL demonstrates biodegradability over a period of 6
months in vivo and is already FDA approved for the use in medical devices234. In addition,
PCL can be mixed and electrospun with ECM proteins such as collagen or fibrinogen that
can allow for additional adhesion ligands for cells post implantation76,223,235. Currently,
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electrospun PCL has been utilized as artificial bone graft scaffolding for bony
reconstruction, conduits for bioengineered arteries and veins, as well as neuronal guides
during nerve approximation allowing axonal growth and guidance236-238. As such, we
decided to focus on the use of PCL polymer to create our blood vessel mimics for in vitro
studies.
Of the critical requirements for cellularization of biomaterials, porosity,
specifically size and 3D architecture of individual pores within a biomaterial plays a key
role to enhance or decrease cellular infiltration both post implantation or through in vitro
methods such as pressure sodding with cells239-241. With regards to electrospun scaffolds,
many evaluate and report in terms of bulk porosity meaning the total volume of porous
space within the scaffold. However, while those measurements are important, at the
cellular level, it is believed that individual pore sizes are the most immediate determinant
of cellular migration, adherence, and infiltration.
Pore sizes are primarily measured through image processing methods in which
electrospun scaffolds are imaged in 2D using multiple microscopy techniques, and from
those images pore sizes are extrapolated242-245. This introduces some difficulty however
because of the high irregularity in random pore shapes and sizes as well as the inability to
approximate overlapping fibers in 3D space utilizing only 2D images. Indeed, multiple
layers of highly randomized fibers are produced during electrospinning and one construct
may be significantly different than another construct if just one spinning parameter is
changed. Alternate imaging modalities create 3D image data via confocal microscopy or
micro CT imaging which are arguably more accurate than 2D image analysis, however,
require longer process times and expensive equipment239,240,244,246-249.

100

The final method to calculate pore size is through mercury porosimetry in which
total volume measurement is produced, yet, pore sizes can be calculated using the
Washburn equation242,250-253. Specifically, one has to make the assumption that the material
being analyzed is in a format resembling bundles of cylindrical tubes, which as mentioned
prior is not an appropriate representation of electrospun scaffolds. In addition, since
porosimetry is a measure of pressure of fluids going through a given material, while pore
size can be calculated, it is only represented as the narrowest points within a given pore.
Herein, we describe the creation of blood vessel mimics using PCL or PCLcollagen I mixtures which can have resistance built in modelling the venturi bypass graft
from arterial to venous intraluminal pressures254,255. In addition, we demonstrate a novel
method for image analysis to gather pore size data for electrospun scaffolds utilizing widely
available ImageJ software and built in functions. We evaluated BVMs with varying pore
sizes to analyze SVF cellular infiltration in conduits exposed to physiological flow rates
and pressures in an in vitro bioreactor over a period of two weeks. In addition, noncellularized, PCL electrospun material was implanted within epididymal adipose tissue in
vivo to analyze cellular infiltration within pore sizes ranging from 1 µm to 8 µm. In vitro
BVMs demonstrated similar SVF cell retention at low pore sizes (1 µm, 2 µm, 5 µm) but
not high pore sizes (8+ µm). In vivo, electrospun material demonstrates insignificant
differences in cellular infiltration in materials of ranging pore sizes at an epididymal
implant location.
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Materials and Methods
Electrospinning
PCL was dissolved using a 5:1 v/v chloroform: methanol solvent mixture at 8%,
13%, and 18% as a weight/volume percentage. In order to achieve smaller pore sizes, 4%
PCL was dissolved in hexafluoro-2-isopropanol. Dissolution was carried out in 20 mL
glass scintillation vials on an orbital shaker overnight. Dissolved PCL was then loaded
into a syringe with a pump and electrospun according to the following parameters:
Solvent
Flowrate

Hexafluoro-2-isopropanol 5:1 Chloroform:Methanol
4 mL/hr

8 mL/hr

Slide Speed

4

4

Rotor Speed

400 rpm

400 rpm

Voltage

22.5 kV

25 kV

25 cm

25 cm

10 mm, 4 mm

10 mm, 4 mm

3.8 cm 18G blunt tip

3.8 cm in 18G blunt tip

Collector Distance
Mandrel Size
Needle type

In order to produce electrospun scaffolds of a more biologically active composition,
we chose to electrospin 3:1 v/v PCL:Collagen I at equivalent pore sizes to the PCL only
counterparts. Briefly, PCL and collagen were dissolved individually into HFP at 4%, 10%,
and 13% as a weight/volume percentage. The 18% solution was attempted but unable to
form stable Taylor Cone and thus unable to be electrospun. Dissolution was carried out in
20 mL glass scintillation vials on an orbital shaker overnight. The next day, PCL and
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Collagen I solutions of the same concentration were mixed together in a 3:1 PCL:Collagen
I ratio volume:volume. The mixture was vortexed for 1 minute and allowed to de-bubble
by gently mixing for at least 1 hour on the orbital shaker before being loaded into a syringe
with a pump and electrospun according to the following parameters:
Solvent

Hexafluoro-2-isopropanol

Flowrate

4 mL/hr

Slide Speed

4

Rotor Speed

400 rpm

Voltage

22.5 kV (4%), 25 kV (10%), 27.5-30 kV (13%)

Collector Distance

25 cm

Mandrel Size

10 mm

Needle type

3.8 cm 18G blunt tip

All electrospun scaffolds were measured such that dispensing volumes of PCL or PCL/Col
created scaffolds of 500 µm thickness. After electrospinning, scaffolds were dried in a
desiccator for at least 12 hours and stored as needed in the desiccator.
Scanning Electron Micrograph Imaging and ImageJ Pore Size Calculation
Dried scaffold samples were sputter coated with gold and then imaged using a JSM820 SEM (Jeol). Sample micrographs were opened in ImageJ and then thresholded to
exclude everything except for the top layer of fibers on the scaffold as determined by image
focus. The thresholded images were processed using ImageJ’s analyze function in terms
of centroid x/y location in addition to major and minor axis lengths in order to calculate
pore sizes. Minor axis lengths shorter than the average fiber width of 10 randomly selected
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fibers were added as an exclusion criterion due to threshold pixilation within single fibers
(termed “railroading”). This size-based thresholding allowed for the removal of pixels and
pixel groups within a fiber that fell below the grayscale threshold and would otherwise
have been counted as false positive pores. The size-based threshold needed to be done
manually as an automated method determining fiber size would include these pixel groups
that would cause single fiber sections to be split into two much thinner fibers, thereby
skewing fiber size results and thus pore size results.
Animals and Ethics Statement
All animal procedures were conducted in compliance with University of Louisville
School of Medicine IACUC-approved protocols and NIH guidelines. Isoflurane gas was
administered for anesthesia.
SVF Isolation from Sprague Dawley Rats
Rat epididymal fat pads were excised from 6 to 8-month-old Sprague Dawley rats
at weights greater than 250g under sterile surgical procedure and isoflurane anesthesia. All
procedures were reviewed and approved under the University of Louisville’s Institutional
Animal Care and Use Committee. Excised fat pads were placed in PBS containing 0.1%
bovine serum albumin (Sigma Aldrich, St. Louis, MO) and kept at 4°C for 15 min prior to
digestion. Samples were washed with BSA-PBS and minced for 2 min until particulates
could pass through a 50mL aspirating pipette. 2mg of Type I Collagenase (Worthington
Biochemical Corporation, Lakewood, NJ) was added per mL of fat, aliquoted at 20mL total
volume in 50mL conical centrifuge tubes, and rotated in an Envirogenie Incubator
(Scientific Industries, Bohemia, NY) at 35 rpm and 37°C for 35 min. Samples were
pelleted via centrifugation at 350xg for 4 min at RT. Buoyant adipocytes were aspirated
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and discarded, and dense cellular pellets were suspended and washed one time in BSAPBS. Samples were re-centrifuged for 4 min at 350xg. The SVF pellet was filtered through
a 250µm mesh filter (Tissue Genesis Incorporated, Honolulu, HA) and collected into
DMEM containing endothelial cell growth supplement, 2mM L-glutamine, 10% fetal
bovine serum, and 5mM Hepes buffer. Samples were kept at RT prior to BVM sodding.
SVF Cell Sodding Electrospun Tubes and Conditions of the Pulsatile Flow Bioreactor
Electrospun 4 mm diameter tubes were cut to lengths of 10 cm and pre-wet for 30
min in Rat complete media at RT. Luer locks were sewed onto both endings and a 18G
8cm blunt end needle attached to a 10 mL syringe was loaded with 5 mL rat complete
media containing 2.512 x 106 rSVF cells. This value was calculated based off of previously
published data demonstrating success in patients when BVM grafts were sodded with 2 x
105 cells/cm2 81. Pressure sodding without exceeding 5PSI forces the liquid media through
the pores of the electrospun material while the cells themselves are trapped and retained
within the pores. Cells were pressure sodded in a vertical fashion slowly dispensing the
5mL mixture without exceeding pressures of 1 PSI.
Sodded grafts were immediately sewn into a bioreactor chamber which features a
luminal inlet, a luminal outlet, and an extra-luminal outlet for dispersion of air or excess
chamber volumes. Sodded electrospun tubes were surrounded by rat complete media that
was changed every other day. Tygon tubing connecting a reservoir tank of 500mL of media
was used as the solution to pass luminally mimicking blood flow utilizing a flow ratecontrolled peristaltic pump (Watson-Marlow, Wilmington, MA). Flow was slowly raised
to a final value of 22mL/min by day 5 in culture. These flow rates were calculated to
provide shear forces of 52 dynes/cm2 resembling endogenous physiological flow pressures
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seen in similar diameter arteries/arterioles in vivo. BVMs were cultured for 14 days prior
to explant for further analysis.
Electrospun Mat Implants in Rat Epididymal Fat
From the 10 mm mandrel PCL electrospun tubes, 6mm flat disks were cut and
sterilized via ethylene dioxide gas for implantation. 6-month-old male Sprague dawley
rats were anesthetized using isofluorane at 5%wt/vol. A midline incision was made, and
PCL disks were implanted into the epididymal fat pads held in place with 5-0 prolene.
Incisions were approximated and closed, and animals were allowed to recover for 30 days.
Animals were anesthestized and sacrificed upon explant where the tissue was removed,
formalin fixed overnight and prepared for paraffin blocking, hematoxylin and eosin
staining, and GS1 immunohistochemistry (n = 8 animals).
Histology and Immunohistochemistry
Following 14 days of bioreactor conditioning, as well as following 30 days of PCL
disk implants, tissue samples were blocked in paraffin after 3% formalin fixation and
sectioned in 6 µm slices. Hematoxylin and eosin (H&E) were used to examine basic
histological tissue structure and cellular infiltration.

Immunoperoxidase staining using

antibodies against Griffonia simplicifolia 1 determined presence of endothelial cells in in
vivo explants. Explanted samples were characterized on an objective scale of 1 to 5 via
blinded methods to analyze presence of inflammatory cells within the biomaterial
(inflammation), the presence and formation of a fibrous capsule surrounding the
biomaterial, vessel presence at the interface of biomaterial and host tissue, patent
microvessel infiltration into the biomaterial, parenchymal and stromal cell incorporation,
fibrosis (granulomatous tissue formation), and necrosis.
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Statistical Analysis
Calculated pore sizes were averaged and plotted using GraphPad Prism v.7
Software (GraphPad Prism, Inc., La Jolla, CA) and analyzed for statistical significance
between groups using ordinary one-way ANOVA and Tukey’s multiple comparisons test.
Statistical analysis of implants of PCL and ePTFE were compared using two-way ANOVA
with multiple comparisons.
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Results
Creating an Electrospun BVM With Built-in Resistance
Electrospun PCL tubes were created in the shape of the venturi possus bypass graft,
using an ‘hour glass shaped’ mandrel, forming a built-in resistor such that when exposed
to lumenal flow, pressure is lowered as fluid travels proximally to distally and out the
venous outflow side. Material deposited evenly on the mandrel with a total wall thickness
of 500 µm, and variation in diameter starting with inflow at 4 mm, resistor in the middle at
1mm, and outflow at 4 mm (Figure 22). Intraluminal pressures of un-sodded grafts were
measured using a mockflow loop and flow meters attached at the inlet side or outlet side.
A range of pressures were recorded as flow rates were varied such that at the highest flow
rate of 72 mL/min, 60 mmHg pressure on inlet (arterial) side and 20 mmHg on outlet
(venous) side were noted (Figure 23).
Creating Electrospun BVMs with Varying Pore Sizes
Variations in spinning parameters allowed for the creation of 4 different porosities
utilizing PCL as the electrospun material. Specifically, when using chloroform and
methanol as the solvents, with a flowrate of 8mL/hr and 25kV, mixing PCL to create 8%
weight/volume gave an average luminal pore size of 1.9 µm, 13% gave an average luminal
pore size of 2.9µm, and 18% gave an average luminal pore size of 5.1µm. Changing the
solvent to hexafluoro-2-isopropanol and decreasing the flowrate to 4mL/hr as well as
decreasing the voltage to 22.5kV afforded a 4% PCL mixture to create an average luminal
pore size of 1.1 µm (Figure 24). These measurements were acquired utilizing 2D images
captured via SEM (Figure 25). Thresholding using 2D SEM images and ImageJ software
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allowed the precise measurement of individual pores after identifying railroading patterns
(Figure 26) and removing false positives (Figure 27).
In addition, after testing multiple mixture ratios of PCL and Collagen I, it was
possible to reproduce similar pore sizes with 3:1 vol:vol of PCL to bovine collagen I
resembling 4%, and 8% PCL only electrospun tubes, i.e. average pore sizes ranging from
1.2 µm to 3.0 µm (Figure 28).
Analyzing Cellular Infilitration Within In vivo Implants of Electrospun PCL
Four varying porosities of electrospun PCL were implanted within rat epididymal
fat tissue, explanted after 30 days, and analyzed on an objective scale of 1-5 for
inflammatory response (relative amount of inflammatory cells present in biomaterial), the
presence and thickness of a fibrous capsule surrounding the biomaterial, the amount of
vascular structures surrounding the biomaterial, the amount of vascular structures
penetrating through the biomaterial, overall parenchymal and stromal cellular
incorporation into the biomaterial, the presence of fibrosis or granulation tissue within the
biomaterial, and the presence of necrosis as compared to ePTFE control. There were no
statistically significant differences in inflammation, capsule formation, vascularization at
interface, fibrosis, and necrosis between the 4 varying porosities of PCL electrospun
implants and the ePTFE control. However, there were statistically significant differences
in vascular penetration of the biomaterial between ePTFE and 4% PCL (p < 0.0001),
between ePTFE and 8% PCL (p < 0.05), between ePTFE and 13% PCL (p < 0.0001) and
between ePTFE and 18% PCL (p < 0.0001) (Figure 29). A sample of explanted 4% PCL
biomaterial and 18% PCL biomaterial are illustrated in Figure 30 demonstrated peri-
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implant vasculature as well as intra-implant penetrating vasculature as highlighted by
arrows.
Analyzing SVF-Sodded Electrospun PCL Tubes Post Two-Week Perfusion in a Bioreactor
SVF sodded PCL constructs were stained with H&E to analyze cellular retention
within the biomaterial at different porosities exposed to physiological flow pressures over
a period of two weeks. SVF cells were retained within the pores of 4% PCL, 8% PCL, and
13% PCL immediately post sodding as seen via SEM images (Figures 31 B, 32 B, 33 B,
34 B). Post two weeks flow, and under H&E assessment, while all constructs had some
cellularity, 18% PCL demonstrated the least amount of nucleated cells retained post
bioreactor flow for 2 weeks (Figure 34 E, F).
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Figure 22: PCL Electrospun Macrovessel Mimic (unsodded). (A) Red arrow: artery
anastomotic site, white arrow: Venturi resistor, blue arrow: vein anastomotic site. (B) The
electrospun graft has 4mm opening diameters (green lines) tapering down to a 1mm
diameter at the Venturi resistor (yellow line). (C) Electrospun macrovessel mounted in a
microcirculation chamber.
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Figure 23:

Intraluminal Pressures Generated Using a Mock Flow Loop and

Microcirculation Chamber Housing PCL Electrospun Macrovessels. Red: Artery end
values. Blue: Vein end values. (n = 2, *** p < 0.001).
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Figure 24: Porosity of 4%, 8%, 13%, and 18% PCL Electrospun Macrovessels as
Measured by 2D SEM. Measurements were taken on both the luminal side (red) and
abluminal side (blue) of the material.
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Figure 25: Scanning Electron Microscopy Images of PCL Electrospun Macrovessels
Demonstating Different Porosities at Different Concentrations of PCL. 4% PCL 200X (A)
750X (E); 8% PCL 200X (B) 750X (F); 13% PCL 200X (C), 750X (G); 18% PCL 200X
(D) 750X (H).
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Figure 26: Representative SEM Image and Thresholding Using ImageJ to Calculate Pore
Sizes of Electrospun PCL. (A) 18% PCL SEM image 400X. (B) Image thresholded to
isolate the top layer of the construct but still demonstrating railroading patterns in
individual fibers based on contrast and pixel density.
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Figure 27: Calculated Pore Sizes Using ImageJ of Non-thresholded and Thresholded
Images. (A) Aggregates of pixel-sized pores representing false positives (red) prior to any
thresholding. (B) True pores labeled in red after pixel-size-based threshold exclusions
applied in ImageJ.
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Figure 28: Pore size of 3:1 Elextrospun PCL: Collagen I at 4% PCL, 10% PCL, and 13%
PCL.
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Figure 29: H&E Determined Scores of Inflammation (A), Capsule Formation (B), Vessels
at Interface (C), Vessel Infiltration (D), Cellular Incorporation (E), Fibrosis (F), and
Necrosis (D) of Implanted Electrospun PCL in Rat Epididymal Fat Pads After 30 Days. *
p < 0.05, **** p < 0.0001.
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Figure 30: H&E and GS1 Immunohistochemistry of Explanted 4% and 18 % Electrospun
PCL after 30 Days in Rat Epididymal Fat. (A) 4% PCL stained with GS1 for endothelial
cells, (B) H&E stain of 4% PCL, (C) 4X zoom of (A), (D) 4X zoom of (B), (E) 18% PCL
stained with GS1, (F) H&E stain of 18% PCL, (G) 4X zoom of (E), (H) 4X zoom of (F.)
Red arrows demonstrate vasculature surrounding the biomaterial, black arrows
demonstrate microvessel penetration into the biomaterial.
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Figure 31: SEM Images and H&E Stained 4% PCL Sodded with SVF Post 2 Weeks Flow
in an In vitro Bioreactor. (A) SEM image of 4% PCL prior to cell sodding. (B) SEM image
immediately after sodding with SVF cells at 2x105 cells/cm2, (C) SEM image of luminal
side of 4% PCL post 2 weeks flow at 22mL/min, (D) SEM image of abluminal side of 4%
PCL post 2 weeks flow at 22mL/min, (E) H&E stained 4% PCL BVM post 2 weeks flow,
(F) 4X zoom of (E); most nucleated cells are sequestered in the first few layers of the
luminal side of the biomaterial.
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Figure 32: SEM Images and H&E Stained 8% PCL Sodded with SVF Post 2 Weeks Flow
in an In vitro Bioreactor. (A) SEM image of 8% PCL prior to cell sodding. (B) SEM image
immediately after sodding with SVF cells at 2x105 cells/cm2, (C) SEM image of luminal
side of 8% PCL post 2 weeks flow at 22mL/min, (D) SEM image of abluminal side of 8%
PCL post 2 weeks flow at 22mL/min, (E) H&E stained 8% PCL BVM post 2 weeks flow,
(F) 4X zoom of (E); most nucleated cells travel through the entire thickness of the
biomaterial.
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Figure 33: SEM Images and H&E Stained 13% PCL Sodded with SVF Post 2 Weeks Flow
in an In vitro Bioreactor. (A) SEM image of 13% PCL prior to cell sodding. (B) SEM image
immediately after sodding with SVF cells at 2x105 cells/cm2, (C) SEM image of luminal
side of 13% PCL post 2 weeks flow at 22mL/min, (D) SEM image of abluminal side of 13%
PCL post 2 weeks flow at 22mL/min, (E) H&E stained 8% PCL BVM post 2 weeks flow,
(F) 4X zoom of (E); most nucleated cells travel through the entire thickness of the
biomaterial, however, less overall cells remain in biomaterial as compared to 8% PCL.
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Figure 34: SEM Images and H&E Stained 18% PCL Sodded with SVF Post 2 Weeks Flow
in an In vitro Bioreactor. (A) SEM image of 18% PCL prior to cell sodding. (B) SEM image
immediately after sodding with SVF cells at 2x105 cells/cm2, (C) SEM image of luminal
side of 18% PCL post 2 weeks flow at 22mL/min, (D) SEM image of abluminal side of 18%
PCL post 2 weeks flow at 22mL/min, (E) H&E stained 8% PCL BVM post 2 weeks flow,
(F) 4X zoom of (E); most nucleated cells travel through the entire thickness of the
biomaterial, however, less overall cells remain in biomaterial as compared to all other
percentages tested of PCL.
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Discussion
Utilizing electrospinning to produce nanofibrous scaffolds for vascular tissue
engineering is a promising technique that has advantages over other fabrication methods.
Firstly, electrospun scaffolds can utilize FDA approved biomaterials that have
biodegradable properties when implanted allowing tissue to encompass and replace the
scaffold. Secondly, electrospinning affords the ability to create fibrous mats or tubes in
which fibers can have tailored diameters of 50 to 500nm in thickness. Additionally, the
randomly distributed nature of fiber deposition can mimic endogenous fibrillar ECM
protein such as collagen I or reticular collagen III seen in specific tissue sites such as
adventitia of larger arteries. These fiber orientations as such also create micropores within
the material allowing for cellular penetration, migration, and infiltration creating microniches for cellular growth and retention.
These pores themselves can be altered by spinning parameters as well and are a
function of fiber size and orientation. There are several thought processes in regard to
cellular infiltration when it comes to electrospun materials.

Many believe that the

orientation of the fibers themselves dictate cellular adhesion geometry and cells tend to
line fibers and attach, if the fiber orientation is unidirectional.

Schoeneberger and

colleagues studied the effects of highly aligned PCL electrospun mats versus randomly
oriented fiber PCL mats on tendon fibroblast adhesion and macrophage MMP
production256.

They concluded that highly aligned electrospun scaffolds tend to

downregulate the expression of MMPs by M2 macrophages which could limit additional
inflammatory response post fibroblast attachment, providing a usable scaffold for tendon
reconstruction in patients with highly inflammatory tissues such as tendonitis.
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Additionally, Tan and colleagues studied endothelial cell attachment to aligned PCL/PEG
electrospun scaffolds and concluded that their bilayer grafts promoted cell adhesion and
ECM production when fibers were oriented in the same direction 257.
Others believe that pore size is more indicative of cellular infiltration into
electropsun materials than fiber alignment. For example, Wang and colleagues prepared a
hybrid method of electrospinning randomly oriented fibrous PCL and electrospraying
poly(ethylene oxide) PEO to create large pores in engineered vascular grafts in which they
noticed increased poor size correlated with increased NIH3T3 cell infiltration with ‘dense
and loose’ layer alternation258.
Our PCL and PCL: Collagen I electrospun grafts, while demonstrating random fiber
deposition, were tailored to produce varying pore sizes in order to analyze sodded SVF
cellular retention within electrospun BVMs mounted in microfluidic chambers exposed to
physiological blood flow pressures; as well as implanted within adipose tissue to analyze
in vivo cellular response and infiltration. We developed a novel technique to analyze pore
sizes using widely available ImageJ software and specific thresholding parameters with 2D
SEM images. We were able to accurately produce measurements of average pore size by
image optimization removing dense pixel false positives and measuring minor axis length
in dead spaces between fibers. Our electrospinning conditions were altered such that pore
sizes ranging from 1 to 5+µm were achieved with varying the fewest parameters possible
between PCL only scaffolds as well as PCL and collagen I mixed material scaffolds.
Interestingly, flow pressures producing 52dynes/cm2 shear allowed cellular
retention in all 4 varying porosities of PCL, however, at the largest pore size (5+µm) the
number of nucleated cells retained were lower than that of the pore sizes ranging from 1 to
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3µm. When embedded into tissue however, all constructs demonstrated similar response
in terms of inflammatory cells present, fibrous capsule formation, peri-implant
vascularization and limited necrosis and fibrosis.

However, electropsun PCL at all

porosities demonstrated higher presence of microvessel penetration into the biomaterial as
compared to ePTFE control. This phenomenon may be attributable to malleability of
material as well as fibrous layout and pore structure allowing for angiogenesis and
endothelial migration through PCL as compared to ePTFE. While average pore sizes were
determined, the random fiber deposition allowed for a wide variability in pore sizes at the
extremes, which may allow microvessels of 10µm or larger in diameter the ability to
penetrate through without the need of degrading or mobilizing PCL fibers. ePTFE does
not afford similar pore sizes and may be a reason for limited microvessel migration through
the material. Additional studies are necessary to elucidate techniques to create even greater
ranges in pore size as well as techniques to introduce additional ECM protein into
electrospinning. Increased cellular retention may occur not only as a condition of porosity
but as a condition of cellular adherence through focal adhesion production and integrin
binding to ECM proteins providing a wide range of materials to test affording both
biodegradability and cellular adhesion and signaling activation.
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CHAPTER IV
SUMMARY AND CONCLUSIONS

Stem and other cell therapeutics demonstrate promising potential for the
stimulation and regeneration of pathological tissues. Ischemic cardiovascular disease is a
leading cause of death in the western world and as such, many cellular-based therapies
have been studied to accelerate myocardial return to function in conjunction with currently
approved pharmacotherapies.

While ischemic cardiomyopathies are composed of

multicellular breakdown and dysfunction, the reestablishment of perfused tissue via macro
and microcirculation is fundamental to mitigate continual tissue necrosis and scarring.
Our group and others have focused on stromal vascular fraction as the cell source
to regenerate microcirculation both in vitro and in vivo. Stromal vascular fraction is a
highly complex and dynamic group of cells that can be easily isolated from tissue sources.
Over the past several decades many have isolated and characterized stromal vascular
fraction from accessible subcutaneous adipose tissue depots in humans and other mammals
via lipoaspiration or other minimally invasive surgical techniques. Many have even
developed companies around proper harvesting and limited tissue manipulation through
the production of automated systems that can accept lipoaspirate and produce injectable
SVF for clinical treatments.

SVF can undergo dynamic cellular re-assortment and

phenotypic modification to produce microvessels with lumens in 3D systems.
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Additionally, upon in vivo implantation, SVF forms robust microvascular networks that
signal with host microvasculature to inosculate, receive circulating blood, and perfuse
surrounding tissue. These exogenous ‘tissue engineered’ vessels remain within the host
tissue and do not undergo extensive pruning or remission.
Due to these phenomena and others, many have studied specific cellular
populations within SVF due to the heterogeneity of cells present, in order to analyze
signaling events necessary for microvascular reformation. SVF contains endothelial cells,
smooth muscle cells, pericytes and perivascular cells, fibroblasts and other stromal cells,
adipose derived stem cells, mesenchymal stem cells, hematopoietic stem cells, and
circulating immune cells depending on hemostasis of the adipose tissue at time of resection
and digestion. These cell types can signal vasculogenic and angiogenic events such that
individual endothelial cells regroup and reorganize into networks which ultimately undergo
tubulogenesis both on specific 2D surfaces and within 3D matrices, in a culture system or
upon implantation.
Endothelial tubes however are not descriptive of functional microvessels and
rather, the multitude of cell types present allows continual maturation via pericyte
recruitment and stabilization through known PDGF-B ligand secretion and signaling. We
were able to analyze these mechanisms and others within angiogenic pathways via our
novel 2D in vitro time-lapse assay whereby inhibitors were added to block known
angiogenic signaling events. We believe that patient SVF can be analyzed prior to use in
a clinical setting for ‘vascular potential’ which may mitigate cost and effectiveness of
treatment if end goals are SVF incorporation and formation of new microvascular tissue.
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Additionally, the delivery of discrete tissue units rather than liquid suspensions of
cells may render larger therapeutic effects due to higher retention at injection sites as well
as the creation of a microenvironment stable enough to allow embedded, exogenous SVF
to mature into microvessels within host pathological tissue. For example, infarct zone post
myocardial infarction if left untreated will form thick dense fibrous scar tissue that is not
amenable to surrounding microvessel infiltration and reperfusion. As such, it is possible
that delivery of larger tissue units of preformed microvessels will respond and integrate
into pathologic tissue more so than cell-suspended solutions at infarct border zones. This
theory has been studied by ourselves and others whereby SVF, whether in the form of a
cardiac patch using VicrylTM mesh support or embedded in 3D collagen I, provides
functional benefits such as increased ejection fraction when implanted on the pericardial
surface of infarcted heart tissue in rats67,139,140. However, the use of additional ECM and
other scaffolds to develop in vitro cardiac patches of SVF microvessels has not been fully
elucidated.
Using digestion protocols to create individual SVF cell suspension, when cultured
in 3D fibrin versus 3D collagen I, freshly isolated SVF undergoes the initiation of tubelike “microvessel” formation in vitro in a time period of 4 days. To form microvessels in
vitro in 3D Collagen I systems, microvessel fragments must be present as the initiator of
angiogenesis and incubation can range from a minimum of 7 days to 14 days to notice
phenotypic change. The role of fibrin specific integrins accelerate signaling between SVF
endothelial cells and ECM stimulating angiogenic events such as tip cell and stalk cell
formation, endothelial cell migration, and tubulogenesis all in a VEGF dependent manner.
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In order to produce and deliver tissue units of SVF, we have developed a system
using bioprinting methods to automate and dispense liquid droplets of collagen I or fibrin
containing SVF, ultimately forming ECM spheroids full of SVF-derived microvessels.
The use of automated systems allows for production of viable tissue in spheroid format,
which is easily dosable and injectable through large gauge syringes. Tissues in spheroid
format also allow for the production of large volumes with limited media in spinner flask
culture. In addition, tissue is in sizes that allow for nutrient diffusion and permeabilization
without production of necrotic cores or zones.
Lastly, we have created a new model to analyze the porosity of electrospun grafts
which may have potential for artificial large vessel creation. SVF can be embedded within
the pores of electropsun PCL and undergo exposure to physiological blood flow in in vitro
bioreactors. Material devoid of cells also shows promising ability of cellular infiltration
and local tissue microvessel penetration as compared to other materials such as ePTFE
upon implantation in vivo.
SVF grown in 3D fibrin in spheroid format may provide clinically translatable
tissue units for treatment of ischemic cardiomyopathies. Microvessels delivered may
inosculate with host microvasculature at border zones of infarct and stimulate reperfusion
at the microcirculatory level in the pathological tissue. Macrovessels of specific porosity
may elucidate artificial blood vessel formats that can be beneficial to patients requiring
CABG without native vessels that can be surgically transplanted. These therapies in the
future may function alongside current standard care treatments to accelerate myocardial
reperfusion post-surgery and mitigate tissue damage at the cellular level. Many additional
experiments are necessary to understand both at the molecular level SVF cellular behavior
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in 3D culture systems as well as at the bioengineering level to produce tissue constructs
that are structurally relevant for surgical applications including both microvessel and
macrovessel morphologies.
Future directions include large animal ischemic infarct models whereby SVF can
be harvested and produced in fibrin spheroid format for injection at border zone areas. In
addition, electrospun sodded macrovessels can be surgically implanted in multiple areas
and anastomosed with host arteries to understand native tissue integration, and host
response creating new arterial tissue.
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